The cause of the increased colon cancer mortality rate in Newfoundland & Labrador: a study comparing survival in Newfoundland & Labrador and Ontario population-based cohorts by Noseworthy, Hayley L.
  
 
 
THE CAUSE OF THE INCREASED COLON CANCER MORTALITY 
RATE IN NEWFOUNDLAND & LABRADOR: A STUDY COMPARING 
SURVIVAL IN NEWFOUNDLAND & LABRADOR AND ONTARIO 
POPULATION-BASED COHORTS 
by Hayley L. Noseworthy 
 
 
A Thesis submitted to the School of Graduate Studies in partial fulfillment of the 
requirements for the degree of 
 
Master of Science in Medicine in Clinical Epidemiology 
Memorial University of Newfoundland 
 
May 2018 
St. John’s, Newfoundland & Labrador 
ii 
 
ABSTRACT 
Background: Colorectal cancer (CRC) is the second leading cause of cancer-related death 
among Canadian men and women.  Newfoundland and Labrador (NL) has the highest CRC 
mortality rate in the country.  To determine whether this resulted from increased CRC incidence, 
later stage or more adverse prognostic factors at diagnosis, or diminished survival by stage, colon 
cancer data was compared from NL (n=510) and Ontario (ON) (n=906) cohorts.      
Methods: Predicted and actual CRC incidence and death rates were obtained.  Survival analysis 
was conducted for stages 1-3 colon cancer patients in the 2 cohorts.  Multivariate models 
included sex, stage and age at diagnosis, microsatellite instability, body mass index, smoking 
status, and adjuvant treatment.   
Results: Estimated age-standardized incidence rates in NL were 34% higher in men and 21% 
higher in women than in ON, comparatively.  Actual NL incidence rates were 55% and 53% 
higher in men and women than estimated.  NL cases had improved survival compared to ON at 
stage 2 (p=.041), otherwise survival by stage was similar.  Other adverse predictors of survival 
were similar between provinces.   
Conclusion: NL’s high CRC mortality rate can be attributed to increased incidence and not to 
adverse prognostic indicators or worse survival.  This data supports the need for improved CRC 
screening strategies.  
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Chapter 1 INTRODUCTION 
Colorectal cancer (CRC) is cancer of the large intestine including cancers of both the 
colon and rectum.  The colon extends from the cecum, or end of the small intestine, to the 
rectum.  The colon is further comprised of the right, transverse, and left colon.  The right side 
includes the cecum, ascending colon, and hepatic flexure.  The left side includes the splenic 
flexure, descending colon, and sigmoid colon.  The rectum then extends from the sigmoid colon 
to the anus. 
Colorectal cancer develops from a polyp, a precancerous bulging tissue mass that 
protrudes from the epithelial lining of the colon or rectum.  Polyps develop on the intestinal wall 
and continue to grow until they develop into a malignant, cancerous tumour.  Adenomas are a 
group of polyps that account for most CRC tumours.1  Adenocarcinoma is then cancer that has 
developed from an adenomatous polyp. 
Polyps may develop sporadically and without underlying heritable contribution, leading 
to sporadic colorectal cancer.  They may also develop due to familial risk where cases present in 
some families at a higher rate than expected by chance.  Familial risk is defined as having two or 
more first- or second- degree relatives with CRC.  Causes of familial cancer development are 
unknown, however possible contributors are similar risk factors in lifestyle, diet or environment. 
Polyps may also develop due to a hereditary condition such as Hereditary Non-Polyposis 
Colorectal Cancer (HNPCC), including cases with Lynch Syndrome (LS) or Familial Colorectal 
Cancer Type X (FCCTX).  LS is an autosomal dominant hereditary predisposition for 
malignancy explained by a germline mutation in a DNA mismatch repair (MMR) gene.2  There 
tends to be multiple generations affected with CRC at an early age (mean of approximately 45 
years) with tumour predominance in the proximal colon and an excess of extracolonic cancers. 
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FCCTX is a condition of autosomal dominant inheritance of CRC that does not have a 
germline MMR mutation but rather has unknown genetic basis.3  Compared to LS, FCCTX 
families have a lower predisposition to CRC (2.3 vs 6.1), are not associated with developing 
extracolonic cancers, tend to have older mean age at diagnosis (50-60 years vs 45 years), and 
tumours are more likely to be located in the distal colon or rectum.  
Whether sporadic, familial, or heritable, distinct characteristics are evident in the pathway 
leading to development of CRC.  There are different implications in treatment, testing for tumour 
markers, follow-up and involvement of family members in sporadic vs hereditary CRC patients 
so it is therefore important to differentiate the underlying nature of CRC. 
 
1.1 Staging 
 CRC is staged at diagnosis to describe the degree to which cancer is present in the body.  
Cancer stage is one of the most important factors in determining prognosis and treatment 
recommendations.  Cases included in this thesis were staged using the guidelines of the 
American Joint Committee on Cancer (AJCC), also known as the TNM system.  The TNM 
system incorporates 3 elements to determine cancer extent: 
- “T” examines the extent of the tumour’s spread through the various layers that comprise 
the wall of the colon and rectum; 
- “N” indicates if or to what extent the cancer has spread to the lymph nodes; 
- “M” describes whether the cancer has metastasized to distant organs. 
 
CRC cases in the Newfoundland Familial Colorectal Cancer Registry (NFCCR) are 
staged at the time of initial diagnosis as stage1-4 using the TNM system as follows: 
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Stage I: (T1, N0, M0 or T2, N0, M0) – Cancer has grown through the muscularis mucosa 
into the submucosa (T1) or may have also grown into the muscularis propria (T2), with no 
spread to lymph nodes or distant sites. 
Stage II: (T3, N0, M0 or T4, N0, M0) – Cancer has grown into outermost layers of the colon 
or rectum but has not reached nearby organs or has grown through wall of the colon or 
rectum into other nearby tissues or organs, with no spread to lymph nodes or distant sites. 
Stage III: (T1, N1, M0 or T2, N1, M0) – Cancer has grown through mucosa into submucosa 
(T1) or may have also grown into muscularis propria (T2). It has spread to 1-3 nearby lymph 
nodes but not distant sites; or (T3, N1, M0 or T4, N1, M0) – Cancer has grown into 
outermost layers of colon or rectum but has not reached nearby organs or has grown through 
wall of colon or rectum and into other nearby tissues or organs. It has spread to 1-3 nearby 
lymph nodes but not distant sites; or (Any T, N2, M0) – Cancer may or may not have grown 
through wall of colon or rectum, has spread to 4 or more nearby lymph nodes, but not spread 
to distant sites. 
Stage IV: (Any T, Any N, M1) – Cancer may or may not have grown through wall of colon 
or rectum and may or may not have spread to nearby lymph nodes.  It has spread to distant 
sites such as the liver, lung, peritoneum, or ovary. 
 
1.2 Colon Cancer versus Rectal Cancer 
Cancer of the colon is the most common of CRCs comprising about 70%, with rectal 
cancer comprising 30%.4  Relatively few studies in the literature differentiate between colon and 
rectal cancer; analyses and results are generally pooled together as CRC.  While CRC is often 
considered to be one disease, colon and rectal cancers are likely to have etiological differences.4-6  
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Modifiable risk factors do not appear to contribute equally to colon and rectal cancers.4,7-10  Even 
right and left subsections of colon cancers may each have distinct etiologies.4  Further, treatment 
recommendations differ for colon and rectal cancers.11  Hereditary CRCs also affect cancers of 
the colon and rectum uniquely.4,12  Another important difference is anatomic in that the distal 
rectum does not have a serosal covering.  Because cancer of the colon or rectum each involve 
unique anatomy and etiology, colon and rectal cancers should be considered different diseases.   
Analyses for this Master’s thesis will focus on cancer of the colon. 
 
1.3 CRC Mortality in Canada 
According to Canadian Cancer Statistics, almost half of all Canadians will develop 
cancer in their lifetime and 1 in 4 Canadians will die from it.  Colorectal cancer is the second 
leading cause of cancer-related death in both men and women in Canada.13  In 2015 there were 
9300 expected CRC-related deaths in Canada, including 5100 men and 4200 women.  Estimated 
age-standardized mortality rates (ASMRs per 100,000 people) of CRC in Canada for 2015 were 
22 in males and 14 in females.   
 
1.4 CRC Incidence and Mortality in Newfoundland & Labrador 
The lifetime risk of developing CRC is 7%.14  Newfoundland and Labrador (NL) has the 
highest incidence of CRC of all the Canadian provinces and 27% higher than the Canadian 
average.15  Green et al (2007) attribute such high incidence of CRC in NL to hereditary factors, 
both familial and genetic.15 
NL has the highest CRC mortality rate in Canada.13  The predicted ASMR for males was 
38 and 21 for females in NL, compared in Ontario (ON) to 20 in males and 13 in females.  ON 
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ASMRs were comparable to the national ASMRs.  In 2015, it was estimated that there would be 
240 expected deaths from CRC in NL.  CRC is the second leading cause of cancer-related death 
for men and third leading cause of cancer-related death for women in NL. 
Higher mortality rates in NL may be due to either increased CRC incidence due to 
hereditary conditions or exposure to modifiable risk factors, worse prognosis at time of 
diagnosis, or level of care and treatment, resulting in lower survival rates.  Known prognostic 
indicators of CRC include stage of disease at the time of diagnosis, age, and tumour 
microsatellite instability (MSI) status.16,17  MSI exists in tumours that exhibit MMR mutations.  
MMR proteins repair sections of DNA by removing sequence errors that can lead to cancer 
development.   
 
1.5 Factors in CRC Incidence and Survival 
1.5.1 Modifiable risk factors 
Evidence in the literature suggests a relationship exists between lifestyle factors, CRC 
incidence, and survival.  Primary prevention of CRC involves controlling modifiable risk factors 
such as diet, obesity, smoking, and alcohol consumption.  Reducing such risk factors could 
substantially decrease the risk of CRC development in the general population and complement 
screening to reduce CRC incidence and improve survival.9 
 
Diet 
Diet is one of the most important modifiable risk factors linked with CRC.  There is 
inconsistency in the literature in attributing specific dietary factors (red meat vs. poultry, fish or 
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plant-sourced proteins, fiber, and fruits and vegetables, among others) to CRC incidence and 
mortality.9,18-20   
Red meat consumption and its relationship to CRC development has been widely studied 
with varying results.  Chan and Giovannucci (2010) report an increase in colon cancer risk and 
adenoma development in people with high red meat intake.9  A meta-analysis of meat 
consumption and CRC similarly concludes that red meat and processed meat increase risk of 
CRC.21  Tumour recurrence, metastasis, and death has been reported significantly higher among 
CRC patients that followed a high processed meat dietary pattern, characterized by high intakes 
of red meat, fish, and processed meat and fish.22  Processed meat may present a stronger risk 
factor than fresh red meat.23,24  There may also be an association between how red meat is 
cooked and CRC risk, as risk may be higher with consumption of heavily browned meat or that 
cooked at high temperatures for a long period of time.9  In contrast, it has also been reported that 
there is little evidence of association between red meat and processed meat consumption and 
CRC risk.18  An NL population study on red meat consumption could not conclude that increased 
red meat consumption increased CRC risk.25  Similar studies in ON populations found that 
consuming a greater amount of red meat increased CRC risk in their population.25,26   
A significant relationship has been reported between pickled red meat consumption and 
increased CRC risk in NL, with a possible dose-response effect.25  Pickled red meat (meat 
preserved in brine solution) is a unique food in NL and is not as commonly consumed in other 
parts of Canada.  Squires et al (2010) compared diets of an NL and ON population.  An ON diet 
may be more representative of the Canadian diet overall as compared to the traditional NL diet.  
Differences noted between NL and ON diets may be indication that red meat intake is more 
7 
 
likely to work in conjunction with other factors such as genetics or environment, rather than 
independently, to predict CRC risk. 
A diet high in caloric intake has been reported to increase CRC risk,19,27-31 while there 
appears to be an inverse relationship between CRC incidence and diets high in protein, fiber, and 
carbohydrates.19,28,32-35  While there has been little research on the effects of diet on CRC 
survival, it has also been reported that a high carbohydrate diet was related to increased CRC 
survival.36 Total fat, saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty 
acids, and cholesterol have not been associated with increased CRC risk.19  
While increasing consumption of fruits, vegetables, and dietary fiber are unlikely to 
prevent most CRCs, health benefits of a fiber-rich diet may be effective in managing chronic 
inflammation associated with gastrointestinal disorders which may play a role in increasing CRC 
incidence risk.9 
 
Alcohol 
There is inconclusive evidence in the literature regarding the relationship between 
alcohol consumption and CRC risk.  A review by Chan and Giovannucci (2010) cites evidence 
that high alcohol consumption increases CRC risk,9 yet other studies have found no impact.19,37 
A study of NL cases showed that the effect of alcohol consumption on developing CRC 
may be worsened by obesity.37  Among obese subjects, alcohol intake was positively associated 
with CRC risk (OR=2.2), increasing in a linear trend with reported increasing number of 
drinking years. 
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Physical activity 
An inverse relationship is consistently reported between physical activity and incidence 
of both colon adenoma and carcinoma in both prospective cohort and case-control studies.9  This 
relationship remains true when controlling for other healthy lifestyle factors and is observed in 
both leisure and occupational physical activity.9  Physically active people have been found to be 
at 20-30% decreased risk of colon cancer incidence compared to those less active.9  Even without 
weight loss, physical activity itself appears to lower risk, and the association appears to be 
stronger for colon cancer than rectal cancer.4,9  Obese individuals with sedentary lifestyles may 
have higher colon cancer risk than obese individuals leading physically active lifestyles, 
particularly in those with high abdominal obesity and waist circumference.38   
 
Obesity & waist circumference 
An association between obesity as measured by Body Mass Index (BMI) and increased 
risk of CRC has been reported.9,39,40  The association appears to be stronger in men than women 
and for colon cancer compared to rectal cancer.5,9,39,41  The mechanism between the obesity and 
CRC incidence relationship is not well-established in the literature,9,38,41 however it may be 
linked to the obesity-induced effects of insulin, leptin, chronic inflammation, and steroid 
hormones.41  Results for women are less consistent than men, possibly due to the effect of 
estrogen on cancer development.4  One study reported that individuals categorized as having an 
overweight BMI had a 30-40% increased colon cancer risk, and those with obese BMI had a 60-
80% increased risk compared to individuals with normal BMI.38,41  Overweight and obese men 
have been found to have similar CRC risk, irrespective of familial risk of cancer.41 
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A relationship also appears between CRC incidence in both men and women and 
abdominal obesity as measured by waist circumference and waist-to-hip ratio.5,9,39  Waist 
circumference may be a stronger predictor of colon cancer risk than BMI.5,38,39  A linear effect 
has been reported between male and female waist size and colon cancer incidence in particular.38 
 
Smoking 
The relationship between cigarette smoking, adenoma formation, CRC incidence and 
CRC survival is well documented.7,9,42,43  A systematic review and meta-analysis of 36 
prospective studies investigated the impact of cigarette smoking on CRC risk.7  Compared to 
patients who never smoked, current smokers had significantly increased risk of CRC incidence 
(RR=1.15) and mortality (RR=1.40).  Current smokers were also more likely to be diagnosed at a 
later stage of disease.  This may be due to more rapid cancer progression or because current 
smokers are less likely to have health-conscious behaviours and practices than never or former 
smokers.  Compared to never smokers, former smokers were at significantly increased risk of 
CRC incidence overall (RR=1.25), and specifically with increased risk for colon cancer 
incidence (RR=1.10) and mortality (RR=1.27).  Further, a significant increased risk of CRC 
incidence and mortality was reported with increasing daily cigarette consumption, as well as a 
dose-response gradient between daily cigarette consumption and CRC mortality. 
Pre-diagnosis cigarette smoking has been associated with diminished survival for patients 
with CRC.42,43  It has been reported that smoking is associated with worse survival particularly in 
patients diagnosed at early stage disease, yet may have a negligible impact on survival for 
patients diagnosed with advanced stage disease.42  
10 
 
Cigarette smoking has been found to increase CRC risk in a NL study population.8    
Former and current smokers were found to have significantly higher risk of CRC incidence than 
non-smokers (OR=1.36 & 1.96).8  Risk increased significantly with the number of smoking 
years, number of cigarettes smoked daily, and pack-years, and decreased significantly with years 
absent from smoking.  There is conflicting evidence that earlier age of smoking initiation 
increases CRC risk.7,8  In comparison with non-smokers, former and current smokers were at 
significantly elevated risk of CRC.8  The association was stronger among cases who consumed 
alcohol and in men.8  
 
1.5.2 Familial CRC 
Family history is a strong predictor of CRC development.  Familial risk is defined as 
having two or more first- or second- degree relatives with CRC.44  Approximately 20% of all 
patients with CRC have a familial predisposition for developing CRC.44 
Green et al (2007) conclude that genetic, or at least familial, factors are responsible for 
the excess cancer incidence in NL compared to the Canadian average. This is supported by the 
significantly higher proportion of high and intermediate risk families when compared to ON and 
other non-Canadian centres.15  Indicators of familial risk were significantly higher in NL 
compared to ON and 13 other population-based studies.  Of NL cases, 31% had at least 1 first-
degree relative affected with CRC, compared to 20.4% in ON.  The NL rate was 85% greater 
than the mean from 5 other non-Canadian centers included in their analysis.   
The island of NL has a geographically and genetically isolated population comprised 
almost entirely of people from a limited founder population.15,45,46  Approximately 95% of 
Newfoundlanders are from specific regions of England and Ireland.15  In contrast, there is 
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considerable ethnic and racial diversity in the ON population and Canadian population overall.  
NL has been the focus of numerous studies on hereditary diseases involving the province’s 
relatively young population of fewer than 20 generations.46  Due to its limited founder 
population, it has been proposed that the high rate of familial CRC in NL is genetic in origin and 
attributable to founder effects.  A founder effect has been observed in several other inherited 
diseases, which are observed at unusually high or low rates in the NL population.15 
 
1.5.3 Hereditary CRC 
Approximately 5-10% of CRC cases can be attributed to dominantly inherited, highly 
penetrant autosomal syndromes.  Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is an 
umbrella term for several hereditary conditions, including Lynch Syndrome (LS) and Familial 
Colorectal Cancer Type X (FCCTX). 
HNPCC and LS are often erroneously referred to synonymously in the literature.  It is 
therefore challenging to distinguish between the two in literature review.  While they are 
overlapping conditions, they are not synonymous.47,48  The term HNPCC was developed to 
identify families who presented with certain criteria as outlined in Amsterdam Criteria I and II 
(Appendix A).  However, with the discovery of the genetic mechanism underlying HNPCC in 
1993, the term HNPCC should have been abolished.   
 
Lynch Syndrome 
LS is a hereditary predisposition to malignancy due to a germline mutation in DNA 
mismatch repair (MMR) genes.48  LS is autosomal dominant where first-degree relatives of 
mutation carriers have a 50% chance of inheritance.49  LS is the most common of hereditary 
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CRCs both in NL15 and globally.44  Approximately 3% of all CRCs present in families with 
LS.16,44  NL has been found to have the highest incidence of LS-related CRC in the world.15   
LS is associated with inherited genetic mutations in at least one of several MMR genes 
that lead to microsatellite instability (MSI).16,44  The human genome contains hundreds of 
thousands of short, repeated sequences of DNA known as microsatellites.44  MMR proteins exist 
naturally in DNA and repair sections of DNA that have not properly replicated by removing 
sequence errors.  Mutations that occur in MMR genes allow for erroneously replicated DNA to 
exist unchecked and thus microsatellites become unstable, leading to cancer development.  
Tumours that exhibit MMR mutations are referred to as exhibiting microsatellite instability 
(MSI).  A tumour that does not exhibit MSI is microsatellite stable (MSS).  MSI is present in all 
LS tumours.   
MSI tumours have low- (MSI-L) or high-frequency (MSI-H) instability.  MSI-L tumours 
show instability in 1 of 5 tumour markers, while MSI-H tumours show instability in at least 2 of 
5 microsatellites.  MSI-L and MSS tumours appear to be phenotypically similar in nature.50  
MSI-H tumours have unique clinical and pathological features and are seen in about 15% of all 
CRC tumours, including hereditary (~3%) and sporadic (~12%) CRC15,16,50  MSI-H tumours are 
found more frequently in the proximal colon,16,44 have unique histopathological features such as 
poor differentiation,16,44 and, when matched for stage, are less aggressive than MSI-L and MSS 
tumours.50  Whether hereditary or sporadic, MSI-H tumours have slightly better prognosis than 
MSS tumours, however respond poorly to the standard 5 FU-based chemotherapy.16,47    
Because MSI is identified in about 12% of sporadic CRC cases, MSI alone is not a 
diagnostic feature of hereditary CRC.  In addition to MMR mutations, environmental and 
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modifiable risk factors such as smoking and diet may also play a role in the development of MSI 
tumours, either acting alone or with MMR mutations.50,51   
While there are no identifiable phenotypic characteristics to distinguish between LS and 
sporadic CRC,3,15,52 there are some identifiable features prevalent in LS families.  LS-related 
CRC tends to present at a younger age of onset, at approximately age 45 years, compared to 
sporadic CRC cases with approximate onset age of 63 years.16,44  LS cases are also at 
substantially elevated risk of developing extracolonic cancers, including gynecological cancers 
such as endometrial and ovarian, as well as cancers of the stomach, small bowel, pancreas, brain, 
and of the upper uroepithelial tract including renal pelvis and ureter.2,44,49,52,53 
 
Familial Colorectal Cancer Type X 
The term Familial Colorectal Cancer Type X (FCCTX) was proposed by Lindor et al 
(2005) to describe families that meet AC but who do not have a germline DNA MMR mutation, 
named “Type X” due to unknown etiology.  Known MMR gene defects account for over 95% of 
mutations that cause LS,54-58 however only 50-60% of families that meet the AC have a germline 
MMR defect.3,59  A large proportion of apparent hereditary CRC families studied in NL 
presented with CRC cases in the absence of an MMR defect, thus not qualifying as LS.45,60   
There are marked differences between LS and FCCTX families.  FCCTX families have 
shown increased incidence of CRC only, yet still less than in germline mutation families.61  
FCCTX families are further characterized as having MSS tumours, lower relative risk of CRC, 
absence of excess extra-colonic tumours, and a later age of onset of CRC compared to LS 
families, at approximately age 60.7 years.16,45,59-62  Compared to LS CRC tumours, FCCTX 
tumours present more frequently in the distal colon.60,62  Stage of disease at diagnosis has not 
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been found to differ between LS and FCCTX cases.62  Studies have more recently shown the 
novel genetic pathways of FCCTX that lead to cancer development.61  
 
1.6 Hereditary Risk Screening 
The Amsterdam Criteria (AC) is a series of criteria originally developed to help 
practitioners systematically identify LS families.15,50  Published in 1991, the AC was eventually 
found to be too strict for clinical use as it excluded patients diagnosed with extracolonic cancers, 
a feature of LS.  To increase sensitivity, AC was modified in 1998 to become Amsterdam 
Criteria II (ACII) and include pathology other than CRC.  Families who meet ACII that have an 
MMR germline mutation are considered LS, while those without a germline mutation are 
FCCTX.   
There is conflicting evidence on the efficacy of the AC.  Some reports have found 
adherence to ACII to be the most effective system to detect HNPCC families,59 while others find 
only 50-60% of families that meet AC have an MMR defect.3  Because FCCTX patients tend to 
develop CRC after age 50, they do not meet the AC and may be missed by this screening criteria 
altogether.   
Green et al (2007) compared NL to ON and 13 non-Canadian population-based cohorts to 
determine the proportion of NL CRC cases that met the AC.  They reported that 3.7% of NL 
cases with high-familial risk met ACII, significantly higher than the aggregate from the high-
familial risk cases from the other cohorts.15  It was higher, although not significantly, compared 
to the ON cohort.15 
The Bethesda Guidelines (BG) were developed by the National Cancer Institute in 1997 
to identify colorectal tumours that should be tested for MSI, with the goal to identify LS 
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patients63 (Appendix B).  To improve function, the guidelines were revised in 2004 to become 
the Revised Bethesda Guidelines (RBG).   
There are reports that challenge the BG’s accuracy and usability in identifying MSI-
potential tumours and LS families.  Evidence suggests strict use of the original BG to identify 
families for gene analysis results in reduced probability of mutation detection.59  In comparing 
RBG and universal MMR screening to identify LS families, one study reported that 1.7% of 
patients met ACII and that, compared to the universal strategy, RBG failed to detect 14.3% of 
cases with LS and 57.1% of cases with probable non-sporadic MSI tumours.51  This means that 
14.3% of LS patients did not meet RBG.  Because the RBG exclude patients over age 60 years, 
adhering to the criteria could miss a substantial number of LS cases.64  Morrison et al (2011) 
implemented a universal approach to LS screening and found it significantly increased the 
detection rate of potential LS patients to 20.7% from 8.5% through adherence to RBG.64  
Adherence to RBG missed 68.4% of MSI-H tumour cases because the patients were over age 60 
years.  While a universal screening paradigm found significantly more MSI-H tumours and 
therefore had increased likelihood of detecting LS families, testing all CRC tumours for MSI 
may not be clinically or financially feasible.   
Differences are evident between LS and FCCTX families in terms of genetic syndrome 
screening, CRC screening, and cancer risk.  Although known hereditary forms of CRC account 
for only 3-5% of all CRCs, it is important to screen for these conditions due to the very high risk 
of disease in these families.  MMR germline mutation carriers are at approximately 80% lifetime 
risk of developing CRC52 as well as at increased risk of developing extra-colonic cancers.  Since 
LS-related CRCs have also been found to respond differently to standard CRC chemotherapies, 
identifying MMR germline mutation carriers will help determine the best course of treatment.49   
16 
 
Failure to detect genetic mutations can pose a serious impediment in implementing a 
comprehensive genetic and clinical screening program in high-risk families.  Genetic screening 
is important in LS and FCCTX cases because of the lack of phenotype presentation in these 
cases.52  At least a three-generation family history has been deemed necessary to adequately 
determine hereditary-associated cancer.44  Genetic testing should take place for LS when ACII or 
RBG have been met.52  Genetic counseling should occur prior to DNA collection and also when 
test results are disclosed.44 
There are benefits of genetic testing beyond identification of hereditary cancer risks.  A 
positive mutation test result has been found to drastically increase patient compliance with 
colonoscopic screening programs.65  There are patient risks associated with genetic testing such 
as psychological distress, anxiety, health insurance issues, and changes in the family dynamic.52  
A risk estimation cut-off that is too high will overlook MMR mutations and lead to possible 
subsequent morbidity and mortality.49  One that is too low will mean unnecessary patient 
investigation that can lead to increased health care costs, patient anxiety, and unnecessary 
invasive clinical screening.49 
Patients with CRC can also present with sporadic MSI tumours unrelated to hereditary 
CRC etiology.  MMR mutations can occur naturally due to methylation of DNA, leading to MSI 
tumours.  This happens more frequently in elderly patients.  Patients who present with sporadic 
MSI CRC tumours tend to be older than patients with MSS tumours due to methylation (non-
hereditary MSI due to natural MMR defects) which increases with advancing age.16   
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1.7 CRC Screening 
CRC screening efficacy is well documented in the literature.9,44,52,66-69  Screening reduces 
CRC incidence through early detection of pre-cancerous polyps.  It also diagnoses CRC in early 
stage of disease therefore improving likelihood of survival.52,66,68  Fecal occult blood testing 
(FOBT) including immunochemical fecal tests (FTi), sigmoidoscopy, and colonoscopy have all 
been shown to decrease incidence and mortality of CRC.52,66,70,71   
The Canadian Task Force on Preventive Health Care (CTFPHC) was established by the 
Public Health Agency of Canada (PHAC) to develop clinical practice guidelines that support 
primary care providers in delivering preventive health care.  In response to lack of national 
guidance and variability in provincial screening programs, the CTFPHC released CRC screening 
recommendations in 2001 for people at normal and above-average risk of developing CRC.72  In 
2016, the CTFPHC released an updated protocol and guidelines to include recommendations on 
appropriate populations to be screened, most appropriate screening tests, and interval and age to 
commence and cease screening.73,74  They recommend screening adults aged 50-74 years at 
population risk for CRC with FOBT, either guaiac fecal occult blood test (gFOBT) or FTi, every 
two years or flexible sigmoidoscopy every 10 years.  They do not recommend screening adults 
aged 75 years and older or using colonoscopy to screen those at population risk unless as further 
follow-up screening post positive FOBT. 
In 2004, the Canadian Association of Gastroenterology (CAG) and the Canadian 
Digestive Health Foundation (CDHF) collaborated to develop guidelines on colon cancer 
screening for people at average risk.75  Given that cancer risk is greatly influenced by age, past 
medical history, and family history, they recommend asymptomatic individuals over age 50 
years with negative family history should undergo average risk screening by method determined 
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by physician, patient preference, evidence and available resources.  They recommend these 
individuals follow one of the following screening strategies: FOBT every 2 years, flexible 
sigmoidoscopy every 5 years, flexible sigmoidoscopy combined with FOBT every 5 years, 
double contract barium enema every 5 years, or colonoscopy every 10 years.  These guidelines 
are in keeping with those recommended by both the American Gastroenterology Association and 
the British Society of Gastroenterology.  The CAG further proposes screening guidelines for 
individuals at increased CRC risk including those with first-degree relatives with CRC, a family 
history suggesting definable genetic abnormality such as LS, Familial Adenomatous Polyposis 
(FAP), or long-standing inflammatory bowel disease.75  In light of technology development and 
advances in clinical knowledge, the CAG released updated guidelines in 2010.76   
The CAG recommends colon cancer screening in Canada should be delivered through a 
programmatic regional or provincial program rather than through opportunistic screening.  
Opportunistic screening is performed outside of an organized screening program and often 
delivered through fee-for-service reimbursement of physicians.  In comparison, programmatic 
population-based screening is an organized screening program that contains an explicit policy 
with specified age categories, a method and interval for screening, a defined target population, a 
management team responsible for implementation, a health care team responsible for decisions 
and care, a quality assurance structure, and a method for identifying cancer occurrence in the 
population.76  Programmatic screening revolves around the quality of the screening process, 
including follow-up with program participants, thus providing greater protection against harms 
of screening including over-screening, poor quality and complications of screening, and poor 
follow-up of those who test positive.76 
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Population-based CRC screening programs are currently in various stages of 
development across Canada.70  In 2007, the Canadian Partnership Against Cancer created the 
National Colorectal Cancer Screening Network (NCCSN) in an effort to bring focus and 
attention to providing organized CRC screening to Canadians.70  The NCCSN collaborates with 
numerous groups at both the national and provincial levels to plan and implement CRC screening 
in Canada.  In an evaluation of CRC screening program adherence by province, the NCCSN 
compiled and analyzed quality indicators of fecal test (FT) screening.70  FTs measure 
microscopic fecal blood amounts as markers that indicate if further colorectal investigation is 
required.  In particular, FTi is gaining popularity in screening programs as it is more sensitive 
than other FTs.  Individuals who test positive for markers in FTs are then referred for 
colonoscopy.   
Of provinces involved, 70.9% of cancer detected by FT screening was diagnosed at early 
stage (1 or 2).  The number of CRC cases diagnosed at later stage of disease should decrease as 
screening programs develop and participant recruitment increases in these programs.  As of late 
2012, CRC screening program adherence had not yet reached the national target of 60%,70 and 
there is evidence to indicate fewer than half of eligible adults have participated in timely CRC 
screening (2012 Canadian Community Health Survey).  The NCCSN further reports that 
screening program adherence in Canada is higher among women than men, and overall 
participation is highest in those ages 70-74 years.70  Positivity rates for FOBT testing is higher in 
males and increases with age.70 
In 2012, NL released the Newfoundland and Labrador Colon Cancer Screening 
Program.70  Program implementation was phased in, first servicing select areas of the province 
and then expanding to include all regions.  FTi screening kits are available to all residents 
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through mailout delivery or through their general practitioner.  The program targets people aged 
50 to 74 years that are at population-risk of developing CRC.  Without a wide-spread provincial 
screening program, individuals residing in rural areas have limited access to screening.  The 
provincial screening strategy campaign in NL is expected to increase screening rates and allow 
for early detection of CRC, resulting in improved CRC-related survival. 
In a 2007 study on CRC screening adherence in population-risk individuals, ON had the 
most up-to-date screening adherence with 20%.  NL had lowest screening adherence at 12.6%.67 
CRC screening rates in Canada have not reached proposed targets.67,70  Guideline 
adherence is impacted by test availability, patient characteristics such as age and gender, and 
public health promotion.  As provincial screening programs become more established, screening 
rates are expected to increase.  Understanding screening rates and adherence allows researchers 
to examine how screening impacts cancer incidence, mortality, and morbidity.   
Colonoscopy surveillance in hereditary CRC families has been found to reduce CRC 
incidence,44,77 and reduce mortality and morbidity by up to 70%.44,77,78  LS families, or those who 
have strong clinical evidence relating to LS, are recommended to get annual colonoscopies 
starting between ages 20 and 25.44  Because of early age of onset and increased risk of associated 
extra-colonic cancers, early and more frequent screening is encouraged for LS families.3,44  
Reports of lower incidence due to screening have been found particularly in the distal colon and 
rectum.66  Screening the proximal colon, where LS cases present more frequently with 
adenomas, can be challenging.66  In cases of FCCTX, it has been recommended that screening 
with colonoscopy start 5-10 years before the age of onset of the earliest family member 
diagnosed with CRC, with a frequency of no less than every 5 years.3  Screening in FCCTX 
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families, as in those with LS, is important as high incidence of adenoma formation can lead to 
carcinoma.   
Hereditary CRC families exhibit a different survival pattern than those with familial or 
sporadic CRC.44  Hereditary colorectal adenomas tend to develop into carcinomas more rapidly 
compared to sporadic polyps.  Annual colonoscopy is recommended for patients with hereditary 
CRC as these polyps experience accelerated carcinogenesis compared to sporadic CRC polyps.  
A sporadic CRC polyp may take 8-10 years to develop into a carcinoma whereas an LS polyp 
can progress to carcinoma in 2-3 years.44  This is evidence in support of more frequent cancer 
screening in hereditary CRC families.   
 
1.8 Treatment 
Surgical procedures most commonly performed in colon cancer treatment include local 
excision or resection to remove polyps or early stage superficial tumours from the colon lining, 
or bowel resection to remove part of the colon and associated lymph nodes. 
Chemotherapy is also a common treatment for colon cancer, depending on the stage of 
disease at diagnosis and if the patient is at high risk of recurrence.  Adjuvant therapy, or 
chemotherapy administered after surgery, is given to reduce risk of recurrence and increase 
likelihood of survival.  In some cases, neoadjuvant therapy, or chemotherapy administered 
before surgery, is given to shrink tumours in an effort to allow surgery and improve outcomes.  
Radiation therapy is not routinely recommended for colon cancer patients. 
The Canadian Cancer Society published Clinical Practice Guidelines (CPGs) for 
management of colon and rectal cancers in the Canadian Cancer Statistics 2011 manual.13  These 
guidelines were developed through Cancer Care Ontario’s Program in Evidence-Based Care to 
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guide patients and practitioners in implementing treatment recommendations.  For stage 1 colon 
cancer, surgical resection alone is the standard treatment recommendation.  For stage 2 cases, 
adjuvant therapy is not routinely recommended unless the patient is at high risk for recurrence in 
which case they may be candidate for adjuvant therapy similar to that recommended for stage 3 
cases.  Stage 3 recommendations include adjuvant therapy.  Recommendations for stage 4 cases 
include combination chemotherapy and possibly targeted therapy.  Several factors must be 
considered when determining best course of treatment including stage of disease at diagnosis, 
location of the tumour, and patient characteristics such as age and risk of recurrence. 
In 1991, the National Institutes of Health (NIH) published adjuvant therapy 
recommendations for patients with colon and rectal cancer.11  For colon cancer, they recommend 
no adjuvant therapy for stage 1 cases.  Adjuvant therapy is also not recommended for stage 2 
cases unless patients present with high-risk features.  They recommend adjuvant therapy for 
stage 3 cases.  Regarding stage 4 cases, the NIH indicate that adjuvant therapy, by definition, is 
not applicable to cases that have metastatic disease, therefore these cases are excluded from their 
recommendations. 
Wirtzfeld et al (2009) investigated concordance with CPGs in NL and ON colon cancer 
patients.79  Patients were from the same data set as this thesis.  Patients in both provinces 
diagnosed at stages 1 and 3 were treated according to CPGs.  The proportion of low- to high-risk 
patients at stage 2 who had adjuvant treatment did not differ significantly between NL and ON.  
While patients diagnosed as high-risk stage 2 were more likely to receive adjuvant treatment than 
low-risk stage 2 patients, other information was used more frequently in addition to CPGs to 
determine best course of treatment for the high-risk cases.79  For example, patient age (<50 
years) influenced their course of treatment more so than risk status.  This is of interest since 
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MSI-H tumours are linked to younger age of onset and also may not respond to widely-used 5-
FU-based standard chemotherapeutics,16 and yet a strong trend of chemotherapy use was 
reported in younger groups, independent of high-risk status.  Local factors such as resource 
allocation and access to treatment may also affect CPG adherence.79 
Treatment management requires the consideration of many patient and tumour 
characteristics.16,80  Boland and Goel (2010) note the potential that no two CRCs are alike, which 
presents a challenging task in treatment planning.16  Understanding variations in clinical 
practices and outcomes will help improve quality of care for patients with CRC. 
 
1.9 Survival 
Stage of cancer at the time of diagnosis is well supported as being the strongest predictor 
of CRC survival.6,12,17,69,80-85  Cases diagnosed at later stage of disease have worse prognosis than 
those diagnosed in earlier stages.   
There is conflicting evidence in the literature regarding gender as a predictive prognostic 
factor in CRC survival.  Some studies have reported that gender had no significant effect on 
survival6,80 while others reported women had improved survival compared to men.1,12,81,86,87 
A meta-analysis of 13 retrospective cohort studies and 1 randomized controlled trial 
reported that females had significantly better overall survival than males.86  After adjusting for 
all known baseline patient characteristics, sex remained an independent prognostic factor in CRC 
survival.  Evidence suggests that CRC survival differences between genders can be attributable 
to hormonal, genetic, immunological, or environmental differences.86,87 
A study on metastatic CRC reported that young women aged 18-44 years survived longer 
than young men, however older women aged 55+ had significantly worse survival than older 
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men.87  Hormones may play a role in CRC prognosis as pre-menopausal women with metastatic 
CRC have shown improved survival, however as they age through menopause, their prognosis 
worsens.   
Patient age at diagnosis is another predictor of CRC survival noted in the literature.1,6,80-
82,87,88  Younger cases tend to have improved survival compared to older cases as prognosis 
diminishes with increasing patient age.  A study on patients under and over age 65 reported that 
cases under age 65 showed improved survival compared to those over age 65.80  CRC was 
diagnosed in older patients at a later stage, which can subsequently influence treatment regimens 
and prognosis. 
It has been reported that patients diagnosed before age 50 show more advanced stage 
disease and have more aggressive tumours compared to patients ages 80+, yet younger patients 
have better survival.1  Worse prognosis in older patients may not be due to delayed diagnosis, but 
rather that delayed diagnosis may be more prevalent in younger patients.  Consequently, 
improved survival in younger patients may be due to their receiving more aggressive treatment.1  
Adjuvant therapy is more frequently administered in younger patients compared to their elderly 
counterparts, and elderly cases also tend to have more comorbidities.88  Treating physicians may 
believe the gain in giving aggressive treatment is reduced by presence of other illnesses and the 
physical toll treatment takes on older patients.   
Adjuvant treatment has a positive effect on prognosis and survival.17,82,84,85  
Improvements in survival due to adjuvant therapy have been reported for advanced CRC, 
including in patients over age 70 years.82 
Adjuvant chemotherapy is associated with improved survival in younger patients, and 
survival trends have differed significantly by age where stage has been associated with 
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significant improvement in survival for patients over age 75.17  Improvement over time in 
younger patients diagnosed at stage 3 in particular has been reported, potentially due to 
improvements in adjuvant treatment for these cases.  Cancer survival is likely to improve with 
advancements in diagnostic and treatment procedures. 
Obesity has been associated with reduced survival after CRC diagnosis.40  A study on 
obesity as measured by BMI and waist-hip circumference in an Asian population reported that 
relative to normal BMI (18.5-24.9), cases categorized as having low (<18.5) and obese (≥30) 
BMI showed worse survival.89 Overweight BMI (25.0-29.9) and waist-to-hip ratio were not 
associated with risk of death in CRC.  BMI as a predictor of CRC mortality is represented in a U-
shaped pattern, where cases in higher and lower BMI categories have worse prognosis. 
BMI may affect colon cancer survival in men and women differently.90  The relationship 
has been reported to be stronger in men in linear fashion across all BMI categories greater than 
25.0, and strongest for BMI ≥32.5.  In women, BMI ≥30 has shown significantly increased risk 
of colon cancer mortality.  Men have a greater tendency for central adiposity which may be a 
contributing factor to the relationship between CRC and poor prognosis.  Prolonged elevated 
insulin levels in high BMI patients may also impact colon cancer survival by acting as a tumour 
growth promoter.  In women, reduced risk may be related to possible protective effects of 
estrogen. 
There is inconclusive evidence on the effects of cigarette smoking on CRC survival.  A 
study conducted on cases of the same cohorts included in this thesis reported pre-diagnosis 
cigarette smoking to be independently predictive of worse prognosis in CRC patients.10  Current 
smoking was significantly associated with increased risk of mortality, and a step-wise gradient 
was reported of decreasing mortality risk with increasing years of smoking abstinence for former 
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smokers.  Smoking was associated with worse prognosis for colon cancer cases specifically, and 
decreased survival was reported in males only.  Smoking was significantly associated with worse 
survival in patients diagnosed in early stage disease, suggesting newly diagnosed patients with 
early stage disease could see survival benefit by immediate smoking cessation.  They also report 
smoking had little impact on survival in MSI-H tumour patients but was associated with high 
mortality risk in cases diagnosed with MSS/MSI-L tumours. 
In contrast, another study reported that smoking is associated with increased CRC 
mortality in both men and women, with a significantly higher mortality risk from rectal cancer in 
males and colon cancer in females.91  Other reports indicate a relationship between smoking and 
increased mortality after CRC diagnosis with especially pronounced negative effects for MSI-H 
cases.92 
Patients that have MSI-H tumours are shown to have better survival rates than those with 
sporadic CRC.12,93-95  Patients with MSI tumours have longer survival times (even when 
diagnosed at stage 4), earlier stage of disease at diagnosis, and are less likely to have metastatic 
cancer compared to MSS patients.16  Evidence shows that the detection of MSI in CRC patients 
is a positive prognostic factor, particularly in young patients.  There is limited evidence in the 
literature to differentiate between how LS MSI and sporadic MSI patients respond to traditional 
chemotherapy treatment.16  Since sporadic MSI CRC cases are more common than LS cases in 
MSI treatment response studies, it is possible that sporadic cases are those represented in these 
treatment studies.16 
In a meta-analysis looking at relationship between MSI and CRC prognosis, they found 
an association between MSI and improved survival of CRC patients.95 They also found a 
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significant beneficial effect of 5-FU therapy for MSS tumour but could not make a clear 
conclusion for MSI tumours.  MSI can be used as a prognostic and predictive marker of survival. 
Investigating colon cancer specifically, one study found MSI-H status is an independent 
prognostic factor that improves survival in colon cancer.12  They found that significantly more 
females than males had MSI-H tumours.  MSI-H was a favorable factor for overall survival.  The 
average age of cases with MSI-H and MSI-L/MSS tumours was the same so improved survival 
was not due to earlier age at diagnosis. MSI-H had a favorable prognosis over MSI-L and MSS 
tumours. 
Another study compared survival of HNPCC patients to sporadic CRC patients diagnosed 
under age 65 years and found that relative survival rates for HNPCC cases were higher than in 
sporadic cases.94  Stage at diagnosis was similar in both groups so this difference was not due to 
stage.  They suggest the malignant potential of HNPCC tumours does not fully develop as it does 
with sporadic cases, and that the same genetic defect that is responsible for the tumour 
development may also reduce the viability of the cancer cells. 
Having family history of CRC is related to increased incidence of the disease however it 
has also been investigated as being a predictor of survival.  Evidence suggests that family history 
itself does not appear to be related to better survival.1,96  Family history showed no significant 
effect on survival.1  Patients with family history of CRC are more likely to have MSI-H tumours, 
and MSI-H cases tend to have improved survival over MSS or MSI-L cases.  Family history has 
been found not to be a determinant of tumour characteristics.1 
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1.10 Thesis Objectives 
The primary objectives of this thesis are: 
1. To assess whether there is a difference in overall survival between NL and ON colon 
cancer patients 
2. To determine why cases from NL appear to have a worse prognosis when diagnosed with 
colon cancer compared to their ON counterparts 
3. To evaluate whether there are differences in mortality, predictors at presentation, and 
treatment associated with colon cancer survival between NL and ON 
 
The secondary objectives of this thesis are: 
1. To develop a strong knowledge of the steps and processes involved in conducting expert 
ethical research that will allow for a future career in clinical epidemiology 
2. To contribute to the knowledge already present in colorectal cancer by providing relevant 
new information for the care and treatment of individuals with colon cancer 
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Chapter 2 METHODS 
2.1 Ethical Considerations 
Ethical approval was sought and granted from the Human Investigation Committee of the 
Faculty of Medicine at Memorial University of Newfoundland.  Data were collected and 
analyzed directly from existing patient files and questionnaires obtained through previous 
research projects in accordance with the Newfoundland Familial Colorectal Cancer Registry 
(NFCCR) and Ontario Familial Colorectal Cancer Registry (OFCCR).  For this thesis project, 
only de-identified patient information using unique personal code was entered into an SPSS 
database.  Electronic files were accessible to the investigator through use of a computer 
password.  All patient files were kept in locked cabinets where only the investigator and 
designated researchers had access. 
 
2.2 Cancer Statistics 
Estimated numbers of new incident cases and age-standardized incidence rates (ASIRs) 
for Canada, ON, and NL were obtained from the Canadian Cancer Statistics (CCS) manual 
(2011).  Actual numbers of new incident cases and ASIRs for Canada were also obtained from 
the CCS manual (2011).  Actual ASIRs in ON and NL were confirmed through reports from 
provincial agencies from 1996-2006, prepared for the Colorectal Cancer Network (CRCNet), an 
initiative of the Canadian Partnership Against Cancer.  Similarly, estimated numbers of new 
incident cases and age-standardized mortality rates (ASMRs) for Canada, ON, and NL were 
obtained from the CCS manual (2011).  The actual number of deaths and ASMRs for Canada, 
ON, and NL were obtained through CCS (2011-2016) and further for ON through provincial 
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agencies as prepared for CRCNet report.  Actual ASMRs for NL were available for 2006, 2009, 
2010 and 2012 only. 
 
2.3 Case Ascertainment 
The NFCCR was established in 1999 through Canadian Institutes of Health Research 
funding and modelled based on the OFCCR.  The NFCCR is a population-based cohort that has 
reported incident cases of colorectal carcinomas identified through the NL provincial cancer 
registry and diagnosed between January 1st, 1999 and December 31st, 2003.  Patient follow-up 
data was collected up to April 30th, 2010.  Patients between the ages of 20 and 74 years and 
diagnosed within the specified inclusion timeframe were invited to participate.  Cases completed 
a family history questionnaire and risk factor questionnaires, and were also asked to provide a 
blood sample and allow access to their tumour tissue and medical records.  For this thesis 
project, 510 incident cases of colon cancer were recruited from the NFCCR.  For deceased 
subjects, their proxies were invited to participate. 
The OFCCR was established in 1997 and is one of several international sites involved in 
the National Cancer Institute-funded Cooperative Familial Registry for Colorectal Studies.  The 
OFCCR utilized the population-based Ontario Cancer Registry to recruit incident colorectal 
cancer diagnoses spanning January 1st, 1997 to December 31st, 2000.  Follow-up data collection 
was completed in 2010 for OFCCR cases.  Registrants with incident cases of colon cancer were 
asked to participate and 906 cases were recruited.  The OFCCR included 25% of low familial 
risk cases.  No proxies were recruited as the OFCCR did not obtain proxy consent, which 
systematically excluded patients who died 1-2 years after diagnosis. 
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An amendment to a previously submitted application was reviewed by the NIH-funded 
Colon Cancer Family Registry Steering and Advisory Committee, the central hub of 
guardianship for several familial colorectal cancer registries including the OFCCR.  Permission 
for the data originally was sought by a previous investigator on a separate CRC research project 
on the adherence to treatment guidelines involving OFCCR participants diagnosed between 
January 1999 and December 2000 only.79  The amended application was submitted and 
subsequently approved which provided data on colon and rectal cancer patients diagnosed over 
the 4-year span between January 1999 and December 2003. 
 
2.4 Data Collection 
Prognostic indicators on each member of the NFCCR and OFCCR were obtained through 
a series of standardized chart reviews including pathology reports, operative records, oncology 
progress notes, and general medical records.  Pathology reports were used to confirm patient 
diagnosis information.  Once consent was obtained, individuals provided information on family 
history, epidemiological data, personal demographics and personal history, and also provided a 
DNA sample and consented to allow researchers access to tissue blocks. 
 
2.5 Survival Analysis Models 
Survival analysis is used for outcome variables that are time-to-event in nature.  Time-to-
event in this case is survival time.  Survival time is defined by the period beginning at time of 
diagnosis and ending at death.  Follow-up was censored in all participants who were still alive at 
the end of the study or lost to follow-up. 
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Kaplan-Meier Survival Analysis 
Kaplan-Meier (KM) survival analysis is a univariate model used to compute the survival 
curves and compare between 2 groups.  The Log-rank test is a chi-squared test that compares 
observed and expected frequencies over categories.  If the Log-rank test is used to compare two 
groups, it tells us if a statistically significant difference exists between the groups.  If Log-rank is 
used to compare more than two groups, it tells us if a significant difference exists overall but not 
between which groups the difference lies.  With KM, survival of different groups can be plotted 
and compared using Log-rank tests.  However, the KM survival analysis does not allow 
assessment of multiple explanatory variables.   
 
Cox Proportional Hazards Multivariate Model 
The Cox Proportional Hazards (CoxPH) Model allows for multivariate modelling 
survival analysis and allows for multiple explanatory (independent) variables.  CoxPH computes 
an estimate of the magnitude of effect for independent variables, which is the Hazard Ratio 
(HR).  The hazard function is the rate (not a probability) at which an event might occur given 
that the subject has survived up until that time.  The precision of this HR estimate is indicated 
using a Confidence Interval (CI) of 95%.  Interaction terms between independent variables can 
also be examined in a CoxPH model.  To meet one of the main model assumptions for CoxPH, 
the HR must be constant over time and the hazard for one group must be proportional to the 
hazard for another group.  To evaluate the Proportional Hazards Model assumption, the log 
minus log (LML) graph function is used.  If the relationship between the 2 groups is 
proportional, the 2 lines will be parallel.  The Omnibus Tests of Model Coefficients (-2 Log 
Likelihood or -2LL test) will verify if the chosen model fits the data better than no model.  For 
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this data, the -2LL value in the Omnibus Tests of Model Coefficients is statistically significant 
with p-value less than 0.05 (p=.000) indicating the CoxPH model fits the data.  
 
2.6 Statistical Analysis 
All data were analyzed using SPSS v.18 (IBM SPSS Inc. (2010)).  Prognostic variables 
included in statistical models were gender, age at time of diagnosis, MSI status, adjuvant 
treatment administered, BMI, smoking status, and stage of disease at time of diagnosis.  Age was 
categorized as ≤49 years, 50-59 years, 60-69 years, or ≥70 years.  MSI status was defined as 
MSI-H (≥30% of markers tested unstable), MSI-low (MSI-L, >0% and <30% of markers 
unstable) or microsatellite stable (MSS).  Treatment included chemotherapy administered pre-
surgery (neoadjuvant) and post-surgery (adjuvant) and excluded palliative chemotherapy.  BMI 
was categorized as Low (BMI <18.5), Normal (BMI 18.5-24.9), Overweight (BMI 25.0-29.9) or 
Obese (BMI ≥30).  Smoking status was defined as never, former, or current smokers.  Never 
smokers were qualified as never having smoked 1 cigarette a day for 3 months or more.  Former 
smokers were those who were still smoking 1 or more cigarettes a day 2 years ago.  Current 
smokers were those who currently smoked 1 or more cigarettes a day.  Stage of disease was 
defined according to the TNM system whereby “T” examines the extent of the tumor’s spread 
through the various layers that comprise the wall of the colon and rectum, “N” indicates if or to 
what extent the cancer has spread to the lymph nodes, and “M” describes whether the cancer has 
metastasized to distant organs. 
Counts and percentages were calculated to describe all categorical variables.  The 
distribution differences between groups were examined by chi-squared (X2) tests.  The Fisher 
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Exact test was used for any expected cells <5.  A statistically significant relationship existed at a 
p-value of less than 0.05. 
KM univariate survival analysis was performed to examine the survival curves between 
the provinces, stratified by stage.  The clinical endpoint of time to death or last follow-up, 
reported in months, was used.  Cases were censored at time of last follow-up, or at any other 
event, if the outcome was not reached.  Because of ascertainment bias in ON, cases from both 
NL and ON diagnosed at stage 4 were excluded from the analysis. 
A Cox PH model for multivariate survival analysis was used to examine the association 
between the independent variables and survival after controlling for prognostic factors. 
NL cases included in this study were compared to 289 NL patients that were in the 
NFCCR but declined study entry to determine if a difference existed between these 2 groups.  
Variables available for inclusion for non-enrolled cases were gender, age at diagnosis, and vital 
status.   
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Chapter 3 RESULTS 
3.1 Predicted Age-Standardized Incidence Rates 
Figures 1A and 1B show the CRC predicted ASIRs for males and females in Canada, 
ON, and NL from 1996-2011.  In 2006, Canada predicted ASIRs for CRC were 62 per 100,000 
in men and 41 per 100,000 in women.  In the same year, ON predicted ASIRs were 61 in men 
and 42 in women, compared to 82 in men and 51 in women in NL.  In men, predicted ASIRs 
were 34% higher in NL than in ON, and 21% higher in NL women compared to ON. 
 
3.2 Actual Age-Standardized Incidence Rates 
Figures 2A and 2B show the CRC actual ASIRs for males and females in Canada, ON, 
and NL from 1996-2006.  In 2006, actual CRC ASIRs in Canada were 60 per 100,000 in men 
and 40 per 100,000 in women.  In 2006 in ON, ASIRs were 60 in men and 40 in women, 
compared to 93 in men and 61 in women in NL.  In men, actual ASIRs were 55% higher in NL 
than in ON.  In women, actual ASIRs were 53% higher in NL than in ON. 
 
3.3 Predicted Number of Deaths 
Tables 1A and 1B show the CRC predicted number of deaths for males and females in 
Canada, ON, and NL for 2006 and 2009, respectively.  In 2006, the total population of Canada 
was estimated at 32,570,505, including 12,661,566 in ON and 510,584 in NL.  In 2009, the total 
population of Canada was estimated at 33,628,571, including 12,997,687 in ON, and 516,729 in 
NL. 
In 2006, Canada predicted CRC-related deaths in 4600 males and 3900 females.  In the 
same year in ON, 1650 and 1450 CRC-related deaths were predicted for males and females, 
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respectively.  In comparison for 2006, 120 deaths in males and 95 deaths in females were 
predicted in NL. 
In 2009, Canada predicted CRC-related deaths in 4900 males and 4200 females.  In the 
same year in ON, 1800 and 1500 CRC-related deaths were predicted for males and females, 
respectively.  In comparison for 2009, 130 deaths in males and 100 deaths in females were 
predicted in NL. 
 
3.4 Predicted Age-Standardized Mortality Rates 
Figures 3A and 3B show the predicted CRC ASMRs for males and females in Canada, 
ON, and NL for 1996 to 2011. 
In 2006, Canada predicted ASMRs for CRC were 27 per 100,000 in men and 17 per 
100,000 in women.  In the same year in ON, ASMRs of 26 in men and 16 in women were 
predicted.  In comparison, ASMRs of 40 in men and 26 in women were predicted in NL.  In 
2006, predicted ASMRs were 54% higher in NL men than in ON men, and 63% higher in NL 
women than ON women. 
In 2009, Canada predicted ASMRs for CRC were 26 per 100,000 in men and 16 per 
100,000 in women.  In the same year in ON, ASMRs of 24 in men and 15 in women were 
predicted.  In comparison, ASMRs of 41 in men and 26 in women were predicted in NL.  
Predicted ASMRs were 71% higher in NL men compared to those in ON, and 73% higher in NL 
women compared to ON. 
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3.5 Actual Number of Deaths 
Tables 2A and 2B show the CRC actual number of deaths for males and females in 
Canada, ON, and NL for 2006 and 2009, respectively.   Actual death counts for NL were 
available for these years only. 
In 2006, there were 4400 CRC-related deaths in males and 3800 in females in Canada.  In 
the same year in ON there were 1650 and 1400 CRC-related deaths for males and females.  In 
comparison for 2006, there were 130 deaths in males and 75 deaths in females in NL. 
In 2009, there were 4600 and 4000 actual CRC-related deaths in Canada in males and 
females, respectively.  In the same year in ON, there were 1650 and 1450 actual CRC-related 
deaths in males and females, respectively.  In comparison, there were 130 deaths in males and 90 
deaths in females in NL. 
 
3.6 Actual Age-Standardized Mortality Rates 
Figures 4A and 4B show the CRC actual ASMRs for Canada, ON, and NL for 2006 and 
2009.  ASMRs for NL were available for these years only. 
In 2006, actual ASMRs for CRC in Canada were 24.8 per 100,000 in men and 15.7 per 
100,000 in women.  In the same year in ON, ASMRs were 24.3 in men and 15.1 in women.  In 
comparison, ASMRs were 42 in NL men and 20 in women.  That year, actual ASMRs were 73% 
higher in NL men than in ON men, and 32% higher in NL women than those in ON. 
In 2009, actual ASMRs in Canada were 23.3 per 100,000 in men and 15.1 per 100,000 in 
women.  In the same year in ON, ASMRs were 22 in men and 14 in women.  In comparison, 
ASMRs were 42 in men and 23 in women in NL.  In 2009, actual ASMRs were 91% higher in 
NL men than ON, and 64% higher in NL women than ON women. 
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3.7 Recruitment 
From Newfoundland and Labrador, 799 patients diagnosed with colon cancer met 
inclusion criteria and were eligible for study enrollment.  Of 799 cases, 510 (63.8%) patients 
consented and enrolled, consisting of 294 (57.6%) males and 216 (42.4%) females.  NL patients 
were eligible for enrollment through proxy consent.  Of 510 cases, 166 (32.5%) enrolled through 
proxy consent and 344 (67.5%) enrolled through direct patient consent (Figure 5). 
From Ontario, 906 patients diagnosed with colon cancer enrolled in the study, comprised 
of 466 (51.4%) males and 440 (48.6%) females (Figure 6).  ON patients were not eligible for 
inclusion through proxy consent therefore all cases from ON were enrolled through direct patient 
consent. 
 
3.8 Patient Demographics and Clinical Characteristics 
Patient demographics and clinical characteristics are seen in Tables 3 and 4.  This 
included cases at stages 1-4, unknown stage, and cases recruited through proxy consent. 
 
Gender 
In the NL dataset, there were 294 (57.6%) males and 216 (42.4%) females compared to 
466 (51.4%) males and 440 (48.6%) females in ON (p=.024). 
 
Age 
Age of patients at time of diagnosis in NL was 60 (11.8%) at age <=49, 128 (25.1%) age 
50-59, 212 (41.6%) age 60-69, and 110 (21.6%) age >=70 years.  In ON, 111 (12.3%) were 
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diagnosed at age <=49, 231 (25.5%) at age 50-59, 419 (46.2%) at age 60-69, and 145 (16.0%) at 
age >=70 years (p=.063).   
 
Adjuvant Treatment 
Adjuvant treatment was administered in 198 (39.1%) of cases in NL and 395 (44.6%) of 
cases in ON (p=.045).  Stratified by stage of disease, a statistically significant relationship was 
evident in stage 3 cases who received adjuvant treatment (p=.017) where significantly fewer NL 
cases diagnosed at stage 3 received adjuvant treatment compared with ON.  When cases 
recruited through proxy consent were excluded from the analysis there was no significant 
difference between the groups (Table 5).   
 
MSI Status 
MSI tumour counts in NL included 71 (14.4%) MSI-H cases and 423 (85.6%) MSI-
L/MSS cases.  In ON, 162 (19.8%) cases where diagnosed with MSI-H tumours and 655 (80.2%) 
cases with MSI-L/MSS.  The difference was statistically significant (p=.012). 
 
BMI 
Excluding cases with unknown BMI, NL BMI category counts included 6 (1.3%) Low, 
140 (31.0%) Normal, 175 (38.7%) Overweight, and 131 (29.0%) Obese.  In ON, 15 (1.8%) cases 
were categorized BMI Low, 288 (34.6%) Normal, 366 (43.9%) Overweight, and 164 (19.7%) 
Obese (Table 6).  The difference was statistically significant (p=.002). 
 
 
40 
 
Smoking Status 
As seen in Table 3, 143 (30.2%) NL cases never smoked, 233 (49.2%) cases were former 
smokers, and 98 (20.7%) were current smokers at time of diagnosis.  In ON, 344 (39.9%) cases 
never smoked, 441 (51.2%) formerly smoked, and 77 (8.9%) were current smokers (p=.000).  
When stratified by sex, statistical significance remained in both males (p=.000) and females 
(p=.000) between NL and ON (Table 7). 
 
Stage at Diagnosis 
When cases between the provinces were compared stratified by stage a statistically 
significant relationship existed (p=.000).  Including all cases diagnosed at stages 1-4 in NL, 73 
(14.3%) were diagnosed at stage 1, 171 (33.5%) at stage 2, 142 (27.8%) at stage 3, and 124 
(24.3%) at stage 4.  In ON, 167 (19.4%) of cases were diagnosed at stage 1 disease, 363 (42.1%) 
at stage 2, 256 (29.7%) at stage 3, and 77 (8.9%) at stage 4.  This difference is likely related to 
the non-recruitment of patients who had died before the study had started, as proxies were not 
allowed from ON. 
 
Excluding Stage 4 Cases 
Excluding stage 4 cases, in NL the proportion of cases diagnosed at stage 1 was 18.9%, 
44.3% at stage 2 and 36.8% at stage 3, and respective proportions in ON were 21.2%, 46.2% and 
32.6% (p=.325). 
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Excluding Proxy Consented Cases 
When the 166 NL cases recruited through proxy consent were excluded and provinces 
were again compared by stages 1-4 (NL=344; ON=863; total=1207) the proportions were 
comparable between provinces (p=.911).  NL cases diagnosed at stage 1 were 66 (19.2%), 140 
(40.7%) at stage 2, 103 (29.9%) at stage 3, and 35 (10.2%) at stage 4. 
 
Non-Enrolled Cases 
Patient demographic characteristics for NL colon cancer cases eligible for study 
enrollment but who declined entry are seen in Table 8.  Groups were compared based on gender 
(p=.140), age at diagnosis (p=.206), and vital status (p=.000). 
 
3.9 Univariate Survival Analysis 
Analysis of all cases including unknown stage cases in ON resulted in a statistically 
significant survival distribution between NL and ON cases (p=.010) with median survival of 94.2 
months in NL and 85.2 months in ON (Table 9).    
Excluding unknown stage cases, a statistically significant survival distribution remained 
for stages 1-4 overall between NL and ON cases (p=.019) with median survival of 94.2 months 
in NL and 84.7 months in ON (Table 10).    
 
Stage 1 
KM analysis of stage 1 cases included 73 from NL with median survival 133.2 months 
and 167 from ON with median survival 101.8 months (p=.760) (Figure 7A, Table 11A). 
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Stage 2 
In NL, there were 171 cases diagnosed as stage 2 with median survival 139.8 months and 
363 cases from ON with median survival 91.0 months (p=.006) (Figure 7B, Table 11B). 
 
Stage 3 
In NL, 142 cases were diagnosed at stage 3 with median survival 105.0 months and 256 
cases in ON with median survival of 77.6 months (p=.259) (Figure 7C, Table 11C). 
 
Stage 4 
Stage 4 case counts for NL and ON were 124 and 77, respectively, with improved 
survival in ON (p=.021).  Median survival was 15.0 months in NL and 30.6 months in ON 
(Figure 7D, Table 11D).  This is likely influenced by selection bias when proxies were not 
enrolled in ON. 
 
Excluding Stage 4 
Due to disproportionately low counts of stage 4 cases in ON, these cases for both 
provinces were excluded and stages 1-3 cases only were included in subsequent survival 
analyses and multivariate modeling.  KM survival analysis of cases diagnosed at stages 1 to 3 
from both provinces resulted in a statistically significant difference in favour of improved 
survival for NL cases (p=.028) (Table 12). 
Median survival in NL cases increased from 94.2 months including stage 4 cases to 133.2 
months excluding stage 4 cases.  In ON, median survival was 84.7 months including stage 4 
cases compared to 89.7 months excluding stage 4 cases. 
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3.10 Multivariate Survival Analysis 
Cox Proportional Hazards Model multivariate survival analysis compared NL and ON 
cases diagnosed at stages 1-3 including variables for gender, stage at diagnosis, age at diagnosis, 
adjuvant treatment, MSI status, BMI, and smoking status (Table 13).  There were 328 NL and 
659 ON cases included in the analysis.   
There was a statistically significant difference in survival between NL and ON cases, 
with improved survival for NL (p=.023).  Additional statistically significant prognostic variables 
included stage of disease at diagnosis (p=.000 for stage 1 compared to 3, and p=.000 for stage 2 
compared to 3), male gender (p=.034), receiving adjuvant treatment (p=.000), and being a never 
smoker compared to a current smoker (p=.040). 
Stage 1 
Analysis of stage 1 cases only revealed no significant differences between provinces 
(Table 14A).   
 
Stage 2 
At stage 2, the survival of colon cancer patients in NL was significantly better compared 
to ON (p=.041) (Table 14B).   
 
Stage 3 
Stage 3 analysis comparing provinces indicated no significant difference (Table 14C). 
 
Independent of adverse prognostic factors at diagnosis, colon cancer patients in NL 
showed significantly improved survival compared to those in ON (p=.023). 
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Chapter 4 DISCUSSION 
 There is a marked difference in both predicted and actual age-standardized CRC 
incidence rates between the Ontario and Newfoundland and Labrador populations according to 
Canadian Cancer Statistics.  In both men and women, NL’s ASIRs are higher than those reported 
in ON, while ON rates are comparable to the Canadian national rate overall.  In men, predicted 
ASIRs were 34% higher in NL than in ON, and 21% higher in NL women compared to ON.  In 
men, actual ASIRs were 55% higher in NL than in ON.  In women, actual ASIRs were 53% 
higher in NL than in ON. 
There is also a clear difference in the age-standardized mortality rates between the 
provinces, where both predicted and actual rates are higher in NL men and women compared to 
ON and Canada rates overall.  In 2009, predicted ASMRs were 71% higher in NL men compared 
to those in ON, and 73% higher in NL women compared to ON.  Actual ASMRs were 91% 
higher in NL men than ON, and 64% higher in NL women than ON women. 
Significant differences are evident in baseline prognostic variables between the NL and 
ON registries.  Compared to ON, NL had a higher proportion of males diagnosed with CRC, a 
lower proportion of cases treated with adjuvant treatment when including cases recruited through 
proxy consent, a lower proportion of cases categorized as MSI-H, a greater proportion of cases 
categorized as obese (BMI ≥30), a greater proportion of cases characterized as current smokers 
at time of diagnosis, and a greater proportion of cases diagnosed at stage 4 disease when 
including cases recruited through proxy consent.   
In univariate analysis of stages 1-4 overall, NL cases showed improved survival 
compared to ON.  When each stage was analysed separately, NL cases had significantly 
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improved survival at stage 2 disease, while ON had significantly improved survival in cases 
diagnosed as stage 4. 
When stage 4 cases were excluded due to the effect of cases recruited through proxy 
consent, univariate survival indicated significantly improved survival for NL cases overall and, 
when stratified by stage, for those diagnosed at stage 2 disease compared to ON. 
In multivariate survival analyses, NL’s improved survival rate remained at stage 2.  There 
was no significant difference in survival between the provinces in cases diagnosed at stages 1 or 
3 of disease.  Prognostic variables significantly related to survival were stage at diagnosis, 
gender, adjuvant treatment, and smoking status. 
Overall, NL cases exhibit a higher rate of CRC incidence compared to their ON 
counterparts, however do not exhibit increased mortality due to CRC. 
 
4.1 Canadian Cancer Statistics 
The Canadian Cancer Statistics (CCS) manual is published annually and reports cancer 
statistics related to predicted and actual incidence and mortality rates in men and women in 
Canada overall and by province.  Provincial cancer registries provide CCS with actual data 
values and consult with CCS affiliates to determine estimated values.  Estimated data are 
determined through statistical models.  Cancer registries reveal patterns that can be observed and 
compared across populations, providing valuable data for cancer research and screening 
programs. 
Actual ASIRs for NL and ON were available up to 2006, thus incidence rates were 
compared and interpreted based on values from that year.  Predicted and actual ASIRs for ON 
were comparable, with ON rates similar to Canadian rates overall.  Predicted ASIRs for NL in 
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2006 were highest by province in Canada, and actual ASIRs for NL were even higher than 
predicted.  NL’s estimated CRC ASIR in 2006 was 6.1% higher than that of ON.  ASIRs were 
higher in males compared to females in Canada, ON, and NL.   
Predicted and actual NL incidence rates are likely higher than reported.  In NL, actual 
mortality rates were not available prior to 2006 as the provincial cancer registry did not receive 
information on cancer-related deaths diagnosed post-mortem through death certificates until 
2005.  As a result, CRC actual incidence in NL may be underestimated.  Case ascertainment for 
incidence and ASIRs of cancers in NL has also been less complete in previous years in 
comparison to those more recent due to lack of reported cases from some regions of the 
province.  Actual incidence values reported prior to 2005 should be interpreted with caution.   
Further, because CCS predicted values are generated through statistical models using 
actual values from previous years, this may provide an explanation for the substantial 
discrepancy between NL predicted and actual values we see in CCS today.  Because actual 
values may be erroneously low, predicted values also appear low.  Further investigation is 
required to determine why NL incidence rates are so high, and why they are so much higher than 
other provinces. 
According to CCS, for the past decade or more NL has had the highest predicted CRC 
mortality rate in Canada.  In 2006, the ASMR for CRC-related death in ON was in keeping with 
the overall Canadian predicted value for men and women.  For NL in the same year, predicted 
ASMRs for men and women were substantially higher than the Canadian average.  In fact, NL 
had the highest predicted ASMR of all provinces in Canada.   
Actual ASMRs for Canada and ON were available up to and including 2006 and for 
2009.  ASMRs for Canada overall and ON were comparable and these values reflected predicted 
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rates.  Actual ASMRs for NL were available for 2006 and 2009 only.  Actual ASMRs for NL 
were higher than all other provinces, but were similar to those values predicted.  ASMRs were 
higher in males compared to females in Canada, ON, and NL.  This investigation was undertaken 
to explore possible causes for such a high mortality rate in NL due to CRC. 
 
4.2 Differences in Prognostic Variables 
A comparison of the NL and ON data sets revealed several statistically significant 
differences in the proportion of prognostic factors that can affect CRC survival.   
A significant relationship existed between province and sex.  There were more males and 
fewer females diagnosed with colon cancer in the NL data compared with ON cases. 
When including cases diagnosed through proxy consent, NL had significant fewer cases 
treated with adjuvant therapy compared to ON.  Stratified by stage, statistically significant 
differences existed between stage 3 cases only.  However, when proxy cases were excluded from 
the analysis, similar frequencies of use of adjuvant chemotherapy were observed, as expected 
from concordance with clinical practice guidelines reported previously.79  Including cases 
recruited through proxy consent, 89.4% of NFCCR stage 3 cases and 95.6% of OFCCR stage 3 
cases received adjuvant treatment.  Excluding proxy cases, 98.1% of NFCCR cases diagnosed at 
stage 3 received adjuvant treatment.   
Compared to ON, NL had a lower proportion of cases categorized as MSI-H.  In the 
literature, one would expect approximately 15% of tumours to present as MSI-H, including 3% 
hereditary and 12% sporadic.  In NL, 14.4% of cases had MSI-H tumours versus 19.8% in ON, 
indicating NL counts were more in keeping with expected values.  Overall in both NL and ON 
there were significantly more MSI-L/MSS tumours than MSI-H. 
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There was an overall statistically significant relationship between province and BMI.  
Compared to ON, NL had a greater proportion of cases categorized as obese (BMI ≥30).  When 
stratified by sex, NL males had significantly higher reported BMI than ON males.  Stratified by 
gender, ON males had a higher reported proportion of Overweight BMI (BMI 25.0-29.9) than 
NL males (55% in ON vs 41.3% in NL), while NL males had a higher reported proportion of 
Obese BMI (BMI ≥30.0) than ON males (33.7% in NL vs 22.4% in ON).   
Increased BMI and waist circumference have been associated with increased risk of CRC 
incidence in the literature.  The association between BMI and CRC appears to be stronger in men 
than in women and for colon rather than rectal cancer development.  There also appears to be a 
dose-response, where higher BMI means higher CRC risk, particularly in men.  Findings in this 
analysis support existing evidence in the literature of the relationship between obesity and colon 
cancer incidence in males.  Compared to the rest of Canada, obesity is more prevalent in the 
Atlantic provinces, including NL.  
Smoking status was significantly different between NL and ON cases.  Compared to ON, 
NL had a greater proportion of cases characterized as current smokers at time of diagnosis 
overall, while ON had a greater proportion of never smokers compared to NL.  By gender, 
females in NL had a significantly higher proportion of current smokers than ON.  Females from 
both provinces had a greater proportion of cases in the never smoker group (45.2% in NL vs 
50.2% in ON) compared to males (19.3% in NL vs 29.9% in ON).   
The literature indicates a relationship exists between smoking and CRC development, 
while the association appears to be stronger in rectal cancer development than colon cancer.  
According to Statistics Canada, by province NL has the highest smoking prevalence in Canada.  
In 2009, NL was above the Canadian average by approximately 3% for smoking prevalence.  
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Prevalence was reportedly higher in males than females.  ON was below the Canadian average 
by approximately 1.5%.   
When including cases recruited through proxy consent, NL had a significantly greater 
proportion of cases diagnosed at stage 4 disease compared to ON.  24.3% of NL cases were 
diagnosed stage 4 while 8.9% of cases were diagnosed stage 4 in ON.  A literature search was 
conducted to determine if stage proportions in the NFCCR and OFCCR cohorts were comparable 
to other population-based studies in Canada.  In particular, stage at diagnosis was compared to an 
incident cohort in ON, diagnosed in 1997-8 in whom ascertainment bias was not limited by age, 
family history, or early death.  NL proportions of advanced disease cases in stages 3 and 4 were 
similar to the literature.  The proportion of cases diagnosed at stage 4 in OFCCR data was 
uncharacteristically low compared to NFCCR cases and the literature.  The proportion of stage 4 
disease was 8.9% in ON, yet one would expect up to 20%.97 
The low proportion of ON stage 4 cases was attributed to lack of proxy consent 
recruitment in the ON registry.  Rather than exclude cases recruited through proxy consent, 
which would cause both NL and ON stage 4 counts to be disproportionately low, all stage 4 
cases were excluded from the survival analysis.  With stage 4 cases excluded, there was no 
significant difference in stage proportion between the provinces. 
When comparing NL cases who were enrolled in the database to those who were eligible 
for enrollment but declined, no significant difference was found in gender or age at diagnosis.  
There was a statistically significant difference between groups in vital status where a greater 
proportion of cases enrolled in the study were deceased compared to non-enrolled cases. 
 
 
50 
 
4.3 Univariate Survival Analysis 
KM univariate survival analysis comparing NL and ON cases diagnosed at stages 1-4 
revealed a statistically significant difference in survival between the provinces.  Stratified by 
stage, a statistically significant difference in survival in stage 2 cases was evident, with improved 
survival for NL cases.   
A significant difference also existed for stage 4 cases as expected, with improved survival 
for ON cases.  The NFCCR recruited cases through both direct patient consent and proxy 
consent.  By nature, cases recruited through proxy consent are more likely to be deceased upon 
entry into the data base.  They are also then more likely to have been diagnosed at advanced 
stage of disease.  The OFCCR recruited cases through direct patient consent only, meaning all 
ON cases had to be alive to be included in the cohort.  Lack of ON’s proxy consent recruitment 
created a survivor bias in the data, particularly obvious when interpreting stage proportions 
between the provinces.   
Stage 4 cases would likely have been more numerous in ON with proxy consent 
recruitment however without proxies the proportion of stage 4 cases appeared low.  Due to 
disproportionately low counts of stage 4 cases in ON, stage 4 cases for both provinces were 
excluded from subsequent survival analyses and multivariate modeling.  In an effort to limit 
survivor bias present in the data, only cases diagnosed at stages 1-3 were henceforth included.  
In univariate survival analyses stratified by stages 1-3 overall, a statistically significant 
difference remained between the provinces.  Excluding stage 4 cases, median survival in NL 
increased from 94.2 to 133.2 months, a difference of 39.0 months.  In ON, median survival 
increased by only 4.1 months, from 85.2 to 89.2.   
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Stratified by stage, NL cases continued to show significantly improved survival 
compared to ON at stage 2 disease.  Contributing factors to this difference in survival were 
unclear and further investigation was required in multivariate modelling to determine why NL 
cases showed improved survival over ON cases diagnosed at stage 2 disease.   
 
4.4 Multivariate Survival Analysis 
Multivariate analysis compared NL and ON cases while controlling for gender, age at 
diagnosis, stage of disease at diagnosis, MSI status, if adjuvant treatment was administered, 
BMI, and smoking status.   
The CoxPH model assumption was evaluated through a graphical technique involving the 
log-log (LML) survival curve to ensure a proportional relationship existed between the variables.  
A proportional relationship was found between the LML curves and therefore amongst the 
variables, indicating that CoxPH model assumptions were met.   
Factors found to independently predict survival between the cohorts included stage at 
diagnosis, gender, adjuvant treatment, and smoking status. 
Independent of adverse prognostic variables at time of diagnosis a statistically significant 
difference existed in survival between NL and ON cases.  Compared to ON, NL showed 
improved survival overall.  Stratified by stage, no difference in survival existed at stages 1 or 3.  
However when diagnosed at stage 2, improved survival was evident in favour of NL cases.  It is 
not clear why such a difference exists at this particular stage and further investigation is required 
to understand this relationship.   
As expected, later stage of disease at diagnosis was an independent predictor of colon 
cancer survival.  Survival decreased with increasing stage at diagnosis.  Compared to stage 1, 
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cases diagnosed at stage 2 and 3 had significantly worse prognosis.  Stage is well known to be 
the strongest predictor of CRC survival in the literature. 
Male gender was found to be a significant predictive factor in multivariate survival 
analysis.  Compared to females, males had worse prognosis.  Although there is some 
inconsistency with evidence in the literature, this finding is consistent with some support in 
previous research. 
Adjuvant treatment was also a significant factor in predicting survival.  Compared to 
those who did not receive adjuvant treatment, cases who did had improved prognosis.  Cases 
diagnosed at later stage of disease are more likely to receive adjuvant therapy in concordance 
with treatment guidelines.  Similar frequencies of use of adjuvant chemotherapy were observed 
between the provinces.  In particular, amongst stage 3 cases, 89.4% of NFCCR and 95.6% of 
OFCCR cases received adjuvant treatment.   
Smoking status was found to be a significant predictor of CRC survival as well.  Cases 
that were categorized as current smokers showed decreased survival compared to never smokers.  
It does not appear that smoking status alone would be responsible for such a high mortality rate 
in NL due to CRC compared to ON and the rest of Canada, however it appears it may be a 
contributing factor.   
In multivariate Cox PH survival analysis, independent of adverse prognostic factors at 
time of diagnosis, the NL cohort showed improved colon cancer survival compared to their ON 
counterparts.  Based on two population-based cancer registries, we can conclude that mortality 
due to colon cancer has not been found to be worse in NL compared to ON cases. 
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4.5 Limitations 
There were several limitations to note in this analysis.  One limitation was survivor bias 
present in the ON data set.  Because proxy consent was not sought from ON cases, those that 
were deceased in ON could not be included in the study.  Cases diagnosed at a later stage of 
disease had lower likelihood of survival, meaning many ON patients who died within 1-2 years 
of diagnosis were systematically excluded from the data set.  Where NL did obtain proxy consent 
and therefore could include information on deceased cases, it appeared that NL had worse 
survival than ON cases.  Stage 4 disease cases were excluded from both NL and ON data sets to 
reduce the effect of evident survivor bias.  In OFCCR another bias occurred as proxies were not 
used to enrol incident cases who died within the first year or so after diagnosis.  Consequently, 
we controlled for this bias by excluding patients with stage 4 disease, patients who were most 
likely not to have been enrolled in the OFCCR.  Exclusion of proxies from the NL sample, which 
makes the research design more comparable to that for ON, favours improved survival in NL. 
Ascertainment bias was also present, as only incident colon cancer patients under 75 
years of age were enrolled in both provinces.  Even though approximately 15-20% of colon 
cancer cases appear in this age demographic, the analysis excluded cases over 75 years of age in 
NL or ON.  This was because both NFCCR and OFCCR data bases did not include incident 
colon cancer cases diagnosed after age 75.  Including cases in people over 75 would have 
furthered the impact of the survivor bias present since ON did not obtain proxy consent.  
Presumably many cases over age 75 would be deceased, and if NL obtained proxy consent from 
these cases but ON did not, the results would be skewed if proxies were included. 
The OFCCR cohort is limited to inclusion of 25% familial colon cancer cases.  The NL 
population is a founder population which includes a greater proportion of familial cancer than 
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other provinces.  It is therefore likely that the NFCCR cohort is comprised of more than 25% 
familial cancer.  Family history of CRC is a factor associated with increased incidence.  Familial 
colon cancer cases have not been found to have improved survival in the literature, however 
cases that have family history of CRC may be more likely to have MSI-H tumours which have 
been found to predict improved survival. 
This study was retrospective in design in which patients are enrolled after treatment for 
CRC.  Data on treatment and outcome has been collected retrospectively.  The limitations of this 
design include potential for lower enrollment rate compared to a design that would enrol patients 
prospectively, inaccuracy associated with chart reviews, and inaccuracy because all relevant data 
may not be recorded in medical charts. 
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CONCLUSION 
The results of this study suggest that NL’s high mortality rate due to CRC cannot be 
attributed to later stage of disease at diagnosis, higher rate of adverse prognostic factors at 
baseline, or to diminished survival following diagnosis.  Survival of NL patients following colon 
cancer diagnosis was not worse than that of ON, and may even be better as shown by comparing 
long term survival rates.  This was not the result of differential use of adjuvant therapy, different 
rates of adverse prognostic factors at baseline, or of ascertainment bias, as failure to enroll 
patients who died soon after diagnosis would favour ON. 
I conclude that NL’s high rate of CRC mortality, the highest in Canada, is as a result of 
also having the highest incidence rate of CRC in Canada.  Consequently, strategies to reduce 
incidence by population-wide primary prevention and screening initiatives are necessary.  CRC 
surveillance in family members of high-risk families may also decrease the incidence of CRC in 
NL.  General practitioners are the first point of patient contact and are the gateway to 
preventative medicine and implementing appropriate cancer screening for their patients.  Contact 
with a general practitioner has been associated with increased CRC screening rates.67  A detailed 
family history is required so that the Amsterdam and Bethesda criteria can be applied where 
necessary.  Due to the high risk of HNPCC families and since the genetic pathway of FCCTX 
remains relatively unknown, priority should be placed on taking a thorough family history, 
especially in NL where hereditary CRC rates are high. 
Early detection and treatment of CRC are crucial.  CRC screening will decrease incidence 
through polyp removal before stage of malignancy.  The mortality rate should also decrease as 
screening can diagnose carcinoma in early stage therefore increasing likelihood of survival.  
There is currently provincial-wide FTi screening accessible to all regions of NL.  Screening 
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promotion through public health outlets and general practitioner contact will remain important in 
encouraging eligible Newfoundlanders and Labradorians to be screened for CRC. 
Many factors can impact CRC survival.  Some have clear indication such as stage at 
diagnosis, while others present with mixed evidence.  Regardless it is clear that screening is 
important to decrease incidence or to diagnose CRC cases in early stage.  Cancer registries are 
valuable tools for analysis of true epidemiological trends.  Interpreting survival patterns is 
important for formulating provincial and national cancer management strategies.   
The implications of these results are that a focus on prevention of CRC is needed.  
Modifying lifestyle factors that are related to decreased survival will likely improve prognosis.  
Promoting a healthy lifestyle and developing health programs to reduce likelihood of CRC 
incidence would be an asset in decreasing the CRC incidence.  Efforts to limit the high rate of 
obesity through promoting healthy dietary habits and physical activity, as well as promoting 
smoking cessation and limiting excessive alcohol consumption are likely to decrease NL’s high 
CRC incidence rates and to play a positive role in decreasing the CRC burden. 
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Table 1A: CRC Predicted Number of Deaths for Males and Females in Canada, ON, and 
NL in 2006 
 
 
 
 
Table 1B: CRC Predicted Number of Deaths for Males and Females in Canada, ON, and 
NL in 2009 
 
 Canada ON NL 
Males 4900 1800 130 
Females 4200 1500 100 
 
  
 Canada ON NL 
Males 4600 1650 120 
Females 3900 1450 95 
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Table 2A: CRC Actual Number of Deaths for Males and Females in Canada, ON, and NL 
in 2006 
 
 
Table 2B: CRC Actual Number of Deaths for Males and Females in Canada, ON, and NL 
in 2009 
 
 Canada ON NL 
Males 4600 1650 130 
Females 4000 1450 90 
  
 Canada ON NL 
Males 4400 1650 130 
Females 3800 1400 75 
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Table 3: Prognostic factors at diagnosis in incident colon cancer patients in NL and ON 
 
 
Colon Cancer Cases 
NL 
N=510(%) 
NL* 
N= 344(%) 
ON 
N=906(%) 
Mean Age 61.4 61.1 60.9 
Sex             
Male 294 (57.6) 197 (57.3) 466 (51.4) 
Female 216 (42.4) 147 (42.7) 440 (48.6) 
Stage 
1 73 (14.3) 66 (19.2) 167 (18.4) 
2 171 (33.5) 140 (40.7) 363 (40.1) 
3 142 (27.9) 103 (29.9) 256 (28.3) 
4 124 (24.3) 35 (10.2) 77 (8.5) 
Unknown 0 0 43 (4.7) 
Adjuvant 
Treatment 
Received 
Yes 198 (38.8) 158 (45.9) 395 (43.6) 
No 309 (60.6) 184 (53.5) 491 (54.2) 
Unknown 3 (0.6) 2 (0.6) 20 (2.2) 
MSI 
High 71 (13.9) 59 (17.2) 162 (17.9) 
Low/Stable 423 (83.0) 273 (79.4) 655 (72.3) 
Unknown 16 (3.1) 12 (3.5) 89 (9.8) 
BMI 
≤18.5 (Underweight) 6 (1.2) 2 (0.6) 15 (1.6) 
18.5-24.9 (Normal) 140 (27.4) 91 (26.5) 288 (31.8) 
25.0-29.9 (Overweight) 175 (34.3) 119 (34.6) 366 (40.4) 
≥30.0 (Obese) 131 (25.7) 91 (26.5) 164 (18.1) 
Unknown 58 (11.4) 41 (11.9) 73 (8.1) 
Smoking 
Status 
Never 143 (28.0) 92 (26.7) 344 (38.0) 
Former 233 (45.7) 162 (47.1) 441 (48.7) 
Current 98 (19.2) 60 (17.4) 77 (8.5) 
Unknown 36 (7.1) 30 (8.7) 44 (4.8) 
*Excluding cases recruited through proxy consent  
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Table 4: Patient demographics compared by province (chi-squared) 
 
  
 X2 p df 
Sex 5.1 .024 1 
Age 7.3 .063 3 
Stage 62.9 .000 3 
Adjuvant treatment 4.0 .045 1 
MSI 6.3 .012 1 
BMI 14.5 .002 3 
Smoking 40.4 .000 2 
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Table 5: Adjuvant treatment administered in NL and ON by stage 
 
 
  
 
Adjuvant 
treatment 
administered 
NL, including proxies 
N=507 (%) 
NL, excluding proxies 
N=342 (%) 
ON 
N=886 (%) 
Stage 1 
Yes 2 (2.7) 2 (3.0) 5 (3.0) 
No 71 (97.3) 64 (97.0) 161 (97.0) 
Total 73 (100) 66 (100) 166 (100) 
Stage 2 
Yes 54 (32.0) 46 (33.3) 132 (36.6) 
No 115 (68.0) 92 (66.7) 229 (63.4) 
Total 169 (100) 138 (100) 361 (100) 
Stage 3 
Yes 126 (89.4) 101 (98.1) 240 (95.6) 
No 15 (10.6) 2 (1.9) 11 (4.4) 
Total 141 (100) 103 (100) 251 (100) 
Stage 4 
Yes 16 (12.9) 9 (25.7) 14 (21.5) 
No 108 (87.1) 26 (74.3) 51 (78.5) 
Total 124 (100) 35 (100) 65 (100) 
71 
 
Table 6: BMI in NL and ON by Gender 
 
  
 BMI 
NL 
N= 452 (%) 
ON 
N= 833 (%) 
Male 
Low <18.5 2 (0.8) 2 (0.5) 
Normal 18.5-24.9 64 (24.2) 94 (22.2) 
Overweight 25.0-29.9 109 (41.3) 233 (55.0) 
Obese ≥30 89 (33.7) 95 (22.4) 
Total 264 (100) 424 (100) 
Female 
Low <18.5 4 (2.1) 13 (3.2) 
Normal 18.5-24.9 76 (40.4) 194 (47.4) 
Overweight 25.0-29.9 66 (35.1) 133 (32.5) 
Obese ≥30 42 (22.3) 69 (16.9) 
Total 188 (100) 409 (100) 
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Table 7: Smoking Status in NL and ON by Gender 
 
 
  
 Smoking Status 
NL 
N= 474 (%) 
ON 
N= 862 (%) 
Male 
Never 53 (19.3) 131 (29.9) 
Former 170 (61.8) 266 (60.7) 
Current 52 (18.9) 41 (9.4) 
Total 275 (100) 438 (100) 
Female 
Never 90 (45.2) 213 (50.2) 
Former 63 (31.7) 175 (41.3) 
Current 46 (23.1) 36 (8.5) 
Total 199 (100) 424 (100) 
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Table 8: Non-Enrolled NL Colon Cancer Cases 
 
 
 
Non-Enrolled NL Colon Cancer Cases N=289(%) 
 
Sex 
Male 151 (52.2) 
Female 138 (47.7) 
Age at diagnosis 
<=49 25 (8.7) 
50-59 67 (23.2) 
60-69 118 (40.8) 
>=70 79 (27.3) 
Vital Status 
Dead 92 (31.8) 
Alive 197 (68.2) 
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Table 9: Univariate Analysis Overall Stages 1-4 and Unknown Stage Cases Comparing NL 
and ON 
 
 
Province 
Mean Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
NL 81.9 2.6 76.8 87.0 94.2 7.6 79.2 109.1 
ON 84.2 1.8 80.6 87.7 85.2 2.7 80.0 90.4 
Overall 85.9 1.6 82.9 89.0 93.8 2.3 89.3 98.4 
 
 
 Chi-Square df Sig. 
Log-Rank (Mantel-
Cox) 
6.677 1 .010 
  
Province Total N N of Events 
Censored 
N Percent 
NL 510 250 260 51.0% 
ON 906 322 584 64.5% 
Overall 1416 572 844 59.6% 
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Table 10: Univariate Analysis Overall Stages 1-4 Excluding Unknown Stage Cases 
Comparing NL and ON 
 
 
 
 
 
 
 
 
Province 
Mean Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
NL 81.9 2.6 76.8 87.0 94.2 7.6 79.2 109.1 
ON 83.6 1.8 80.0 87.2 84.7 2.7 79.4 90.0 
Overall 85.5 1.6 82.4 88.6 93.8 2.7 88.6 99.0 
 
 
  
Province Total N N of Events 
Censored 
N Percent 
NL 510 250 260 51.0% 
ON 863 314 549 63.6% 
Overall 1373 564 809 58.9% 
 Chi-Square df Sig. 
Log-Rank (Mantel-
Cox) 
5.484 1 .019 
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Table 11A: Univariate Survival Analysis for Stage 1 Colon Cancer in NL & ON 
 
 
 
Province 
Mean Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
NL 107.3 5.5 96.4 118.1 133.2 15.7 102.3 164.0 
ON 103.9 4.2 95.6 112.1 101.8 5.89 90.3 113.3 
Overall 106.8 3.4 100.2 113.4 107.6 4.4 99.0 116.2 
 
  
Province Total N N of Events (%) 
Censored 
N Percent 
NL 73 21 52 71.2% 
ON 167 30 137 82.0% 
Overall 240 51 189 78.8% 
 Chi-Square df Sig. 
Log-Rank (Mantel-
Cox) 
.093 1 .760 
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Table 11B: Univariate Survival Analysis for Stage 2 Colon Cancer in NL & ON 
 
 
 
 
 
 
 
 
Province 
Mean Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
NL 108.2 3.8 100.7 115.7 139.9 --- --- --- 
ON 88.0 2.6 82.8 93.1 91.0 5.5 80.3 101.8 
Overall 97.1 2.4 92.5 101.8 101.9 4.745 92.6 111.2 
 
  
Province Total N N of Events 
Censored 
N Percent 
NL 171 51 130 70.2% 
ON 363 112 251 69.1% 
Overall 534 163 371 69.5% 
 Chi-Square df Sig. 
Log-Rank (Mantel-
Cox) 
7.704 1 .006 
78 
 
Table 11C: Univariate Survival Analysis for Stage 3 Colon Cancer in NL & ON 
 
 
 
 
 
 
 
 
Province 
Mean Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
NL 87.8 4.7 78.7 97.0 105.0 8.1 89.1 120.9 
ON 79.6 3.5 72.8 86.5 77.6 3.9 69.9 85.2 
Overall 86.6 3.0 80.8 92.4 88.3 4.5 79.4 97.1 
 
 
 Chi-Square df Sig. 
Log-Rank (Mantel-
Cox) 
1.277 1 .259 
  
Province Total N N of Events 
Censored 
N Percent 
NL 142 62 80 56.3% 
ON 256 104 152 59.4% 
Overall 398 166 232 58.3% 
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Table 11D: Univariate Survival Analysis for Stage 4 Colon Cancer in NL & ON 
 
 
 
 
 
 
 
 
Province 
Mean Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
NL 25.6 2.6 20.6 30.6 15.0 2.1 10.8 19.2 
ON 34.8 2.8 29.4 40.2 30.6 2.2 26.3 34.8 
Overall 29.4 2.0 25.6 33.2 21.0 1.9 17.3 24.7 
 
 
 Chi-Square df Sig. 
Log-Rank (Mantel-
Cox) 
5.368 1 .021 
  
Province Total N N of Events 
Censored 
N Percent 
NL 124 116 8 6.5% 
ON 77 68 9 11.7% 
Overall 201 184 17 8.5% 
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Table 12: Univariate Analysis Overall Stages 1-3 Comparing NL and ON 
 
 
 
 
 
 
 
 
Province 
Mean Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
NL 100.0 2.7 94.7 105.3 133.2 21.7 90.5 175.8 
ON 88.6 1.9 84.8 92.3 89.7 3.2 83.5 96.0 
Overall 95.5 1.7 92.2 98.7 101.2 3.0 95.4 107.1 
 
 
 Chi-Square df Sig. 
Log-Rank (Mantel-
Cox) 
4.841 1 .028 
 
  
Province Total N N of Events 
Censored 
N Percent 
NL 386 134 252 65.3% 
ON 786 246 540 68.7% 
Overall 1172 380 792 67.6% 
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Table 13: Multivariate Survival Analysis Stages 1-3 
 
 
 Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
NL compared to 
ON 
.023 .753 .589 .961 
Males compared 
to females 
.034 1.305 1.021 1.669 
Receiving 
compared to not 
receiving 
adjuvant 
treatment 
.000 .486 .337 .699 
Never smokers 
compared to 
current smokers 
.040 .663 .448 .981 
Stage 1 compared 
to Stage 3 
.000 .198 .121 .324 
Stage 2 compared 
to Stage 3 
.000 .385 .268 .552 
 
  
 N = 1172 (%) 
Cases available in analysis 
Event 316 (27.0) 
Censored 671 (57.3) 
Total 987 (84.2 
Cases dropped 
Cases with missing values 185 (15.8) 
Censored before earliest event 0 
82 
 
Table 14A: Multivariate Survival Analysis Stage 1 
 
 
 Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
NL compared to 
ON 
.213 1.647 .751 3.609 
  
 N = 240 (%) 
Cases available in analysis Event 39 (16.3) 
Censored 158 (65.8) 
Total 197 (82.1) 
Cases dropped Cases with missing values 42 (17.5) 
Censored before earliest event 1 (0.4) 
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Table 14B: Multivariate Survival Analysis Stage 2 
 
 
 Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
NL compared to 
ON 
.041 .669 .455 .983 
  
 N = 534 (%) 
Cases available in analysis Event 133 (24.9) 
Censored 308 (57.7) 
Total 441 (82.6) 
Cases dropped Cases with missing values 92 (17.2) 
Censored before earliest event 1 (0.2) 
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Table 14C: Multivariate Survival Analysis Stage 3 
 
 
 Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
NL compared to 
ON 
.079 .711 .486 1.040 
 
 
 
 
  
 N = 398 (%) 
Cases available in analysis 
Event 144 (36.2) 
Censored 203 (51.0) 
Total 347 (87.2) 
Cases dropped 
Cases with missing values 51 (12.8) 
Censored before earliest event 0 
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Figure 1A: CRC Predicted Age-Standardized 
Incidence Rates - Males (1996-2011)
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Figure 2A: CRC Actual Age-Standardized Incidence Rates 
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Figure 3A: CRC Predicted Age-Standardized Mortality 
Rates - Males (1996-2011)
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Figure 4A: CRC Actual Age-Standardized Mortality Rates -
Males (2006, 2009)
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Figure 5: NL Participant Recruitment  Eligible for study enrollment 
n=799 
Did not consent to enroll 
n=289 
Consented to enroll 
n=510 
 
Male=294 (57.6%) 
Female=216 (42.4%) 
 
Stage 1: n=73 (14.3%) 
Stage 2: n=171 (33.5%) 
Stage 3: n=142 (27.8%) 
Stage 4: n=124 (24.3%) 
Unknown stage=0 (0%) 
 
Enrolled through direct 
patient consent 
n=344 
Male=197 (57.3%) 
Female=147 (42.7%) 
 
Stage 1: n=66 (19.2%) 
Stage 2: n=140 (40.7%) 
Stage 3: n=103 (29.9%) 
Stage 4: n=35 (10.2%) 
Unknown stage=0 (0%) 
 
Enrolled through proxy 
consent 
n=166 
 
Male=97 (58.4%) 
Female=69 (41.6%) 
 
Stage 1: n=7 (4.2%) 
Stage 2: n=31 (18.7%) 
Stage 3: n=39 (24.5%) 
Stage 4: n=89 (53.6%) 
Unknown stage=0 (0%) 
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Figure 6: ON Participant Recruitment 
Consented to enroll 
n=906 
 
Male=466 (51.4%) 
Female=440 (48.6%) 
 
Stage 1: n=167 (18.4%) 
Stage 2: n=363 (40.1%) 
Stage 3: n=256 (28.3%) 
Stage 4: n=77 (8.5%) 
Unknown stage=43 (4.7%) 
 
Excluded from survival analysis 
because stage at diagnosis 
unknown 
n=43 
Included in survival analysis 
n=863 
 
Male=444 (51.4%) 
Female=419 (48.6%) 
 
Stage 1: n=167 (19.4%) 
Stage 2: n=363 (42.1%) 
Stage 3: n=256 (29.7%) 
Stage 4: n=77 (8.9%) 
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Figure 7A: Univariate Survival Analysis for Stage 1 Colon Cancer in NL & ON 
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Figure 7B: Univariate Survival Analysis for Stage 2 Colon Cancer in NL & ON 
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Figure 7C: Univariate Survival Analysis for Stage 3 Colon Cancer in NL & ON 
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Figure 7D: Univariate Survival Analysis for Stage 4 Colon Cancer in NL & ON 
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APPENDIX A 
Amsterdam Criteria I (1991) 
• At least three relatives have histologically verified colorectal cancer (CRC); one of them 
should be a first-degree relative of the other two.  Familial adenomatous polyposis (FAP) 
should be excluded 
• At least two successive generations should be affected 
• One of the relatives should be below 50 years of age when the CRC is diagnosed 
 
Amsterdam Criteria II (1998) 
• There should be at least three relatives with an HNPCC-associated cancer (CRC, 
endometrial, small bowel, ureter, or renal pelvis malignancy) 
• One affected relatives should be a first-degree relative of the other two 
• At least two successive generations should be affected 
• At least one malignancy should be diagnosed before age 50 years 
• FAP should be excluded in the CRC(s) 
• Tumours should be verified by pathological examination 
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APPENDIX B 
Original Bethesda Guidelines (1997) 
Tumours should be tested for MSI in the following situations: 
• Individuals with cancer in families that meet the Amsterdam Criteria 
• Individuals with two HNPCC-related cancers, including synchronous and metachronous 
CRCs or associated extracolonic cancers* 
• Individuals with CRC and a first-degree relative with CRC and/or HNPCC-related 
extracolonic cancer and/or a colorectal adenoma; one of the cancers diagnosed at age less 
than 45 years, and the adenoma diagnosed at age less than 40 years 
• Individuals with CRC or endometrial cancer diagnosed at age less than 45 years 
• Individuals with right-sided CRC with an undifferentiated pattern (solid/cribriform) on 
histopathology diagnosed at age less than 45 years 
• Individuals with signet-ring-cell-type CRC diagnosed at age less than 45 years 
• Individuals with adenomas diagnosed at age less than 40 years 
 
Revised Bethesda Guidelines (2004) 
Tumours should be tested for MSI in the following situations: 
• CRC diagnosed in a patient who is less than 50 years of age 
• Presence of synchronous, metachronous colorectal, or other HNPCC-associated 
tumours*, regardless of age 
• CRC with the MSI-H histology diagnosed in a patient who is less than 60 years of age 
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• CRC diagnosed in one or more first-degree relatives with an HNPCC-related tumour, 
with one of the cancers being diagnosed under age 50 years 
• CRC diagnosed in two or more first- or second-degree relatives with HNPCC-related 
tumours, regardless of age 
 
*HNPCC-related tumours include colorectal, endometrial, stomach, ovarian, pancreas, ureter and 
renal pelvis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumours, 
sebaceous gland adenomas and keratoacanthomas in Muir-Torre syndrome, and carcinoma of the 
small bowel. 
 
 
